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Abstract 
Latent transforming growth factor β (TGF-β) binding proteins (LTBPs) -1, -3 and -4 are 
ECM components whose major function is to augment the secretion and matrix targeting 
of TGF-β, a multipotent cytokine. LTBP-2 does not bind small latent TGF-β but has 
suggested functions as a structural protein in ECM microfibrils. In the current work we 
focused on analyzing possible adhesive functions of LTBP-2 as well as on characterizing 
the kinetics and regulation of LTBP-2 secretion and ECM deposition. We also explored 
the role of TGF-β binding LTBPs in endothelial cells activated to mimic angiogenesis as 
well as in malignant mesothelioma. 
We analyzed numerous cell lines for their ability to adhere to purified recombinant 
LTBP-2. We found that, unlike most adherent cells, several melanoma cell lines adhered 
to LTBP-2 in an efficient and concentration dependent manner. Characterization of the 
most strongly adhering cell line with function blocking anti-integrin antibodies revealed 
that the adhesion was mediated by α3β1 and α6β1 integrins. In addition, soluble heparin 
inhibited the melanoma cell adhesion suggesting a role for heparan sulphate 
proteoglycans. Unexpectedly, the adhesion was not mediated by the N-terminal RGD 
sequence but was located to an adjacent proline-rich region. LTBP-2 was also identified as 
a haptotactic substrate for melanoma cell migration. 
The deposition of latent TGF-β binding LTBPs to the ECM exhibit distinct distribution 
profiles. We used cultured human embryonic lung fibroblasts to analyze the temporal and 
spatial association of LTBP-2 into ECM. By immunofluorescence we found that LTBP-2 
was efficiently assembled to the ECM only in confluent cultures following the deposition 
of fibronectin (FN) and fibrillin-1. Analysis by metabolic labeling and 
immunoprecipitation showed that LTBP-2 was rapidly secreted and subsequently 
associated with the ECM in confluent cultures whereas in early, subconfluent cultures it 
remained primarily in soluble form after secretion. LTBP-2 colocalized transiently with 
FN and failed to assemble to the ECM of FN deficient mouse fibroblasts. Partial 
colocalization of LTBP-2 and fibrillin-1 was also observed in the ECM of fibroblasts, 
MG-63 osteosarcoma cells and human vascular endothelial cells. Silencing of fibrillin-1 
expression by lentiviral shRNAs profoundly disrupted the deposition of LTBP-2 
indicating that the matrix association of LTBP-2 depends on a pre-formed fibrillin-1 
network. 
Considering the established role of TGF-β as a regulator of angiogenesis we induced 
morphological activation of endothelial cells by phorbol 12-myristate 13-acetate (PMA) 
and followed the fate of LTBP-1 in the endothelial ECM. This resulted in profound 
proteolytic processing of LTBP-1 and release of latent TGF-β complexes from the ECM.  
The processing was coupled with increased activation of MT-MMPs and specific 
upregulation of MT1-MMP. The major role of MT1-MMP in the proteolysis of LTBP-1 
was confirmed by suppressing the expression with lentivirally induced short-hairpin 
RNAs as well as by the inhibition with tissue inhibitors of metalloproteinases (TIMPs) -2 
and -3.  
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Malignant mesothelioma (MM) is an aggressive tumor of the pleura with poor 
prognosis. TGF-β can promote mesothelioma tumorigenesis through multiple 
mechanisms. We investigated the expression patterns of different TGF-β and LTBP 
isoforms in MM biopsies and in two established MM cell lines. TGF-β activity was 
analyzed in a panel of MM tumors by immunohistochemical staining of phosphorylated 
Smad-2 (P-Smad2). The tumor cells were strongly positive for P-Smad2 whereas LTBP-1 
immunoreactivity was abundant in the stroma, and there was a negative correlation 
between LTBP-1 and P-Smad2 staining. In addition, the high P-Smad2 immunoreactivity 
correlated with shorter survival of patients. TGF-β1 was the most highly expressed 
isoform in both normal human pleura and MM tissue as assessed by quantitative RT-PCR. 
LTBP-1 and LTBP-3 were both abundantly expressed. mRNA analysis of cell lines 
showed that LTBP-1 was the predominant isoform in MM cells whereas the expression of 
LTBP-3 was markedly high in non-malignant control cells. Suppression of LTBP-3 
expression by siRNAs resulted in increased TGF-β activity in MM cell lines accompanied 
by decreased proliferation of MM cells.  Our results suggest that decreased expression of 
LTBP-3 in MM could alter the targeting of TGF-β to the ECM and lead to its increased 
activation. 
The current work emphasizes the coordinated process of the assembly and appropriate 
targeting of LTBPs with distinct adhesive or cytokine harboring properties into the ECM.     
The hierarchical assembly may have implications in the modulation of signaling events 
during morphogenesis and tissue remodeling. 
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1 Review of the literature 
1.1 Extracellular matrix 
Extracellular matrix (ECM) is composed of diverse components which form complex 
networks where cells are embedded to form tissues (Aumailley and Gayraud 1998; Nelson 
and Bissell 2006). ECM provides the cells with structural support for adhesion and 
migration and defines the organ specific architecture of tissues. It also acts as storage for 
growth factors and signaling molecules affecting their activity and availability (Taipale 
and Keski-Oja 1997; Streuli 1999). The interactions between cells and ECM regulate 
many fundamental processes during the normal development as well as in disease (Nelson 
and Bissell 2006). Despite the diversity of ECM molecules most of them share similar 
structural domains. Thus the function of the ECM is not solely dependent on single 
molecules but on the multiprotein polymeric assemblies.  
 
1.1.1 Structure 
ECM structures can be classified into the interstitial matrix, which accounts for the 
connective tissue of different types, and the basement membrane, which lines the 
endothelium and epithelium separating them from the underlying stroma. 
1.1.1.1 Interstitial matrix 
Interstitial matrix is a highly hydrated fibrillar network that fills the space between the 
cells and determines the physical properties of the given tissue. It can comprise greater 
mass of an organ than the cells that produce its components. The main constituents of the 
interstitial ECM are proteoglycans (PGs) and fibrillar proteins, such as collagen, 
fibronectin (FN) and elastin, and they are primarily produced by fibroblasts. The aqueous 
environment of polysaccharide gels allows rapid diffusion of small molecules such as 
salts, nutrients and hormones whereas the protein components provide support and 
adhesion sites for cells. The relative amounts of matrix components vary and give rise to a 
diversity of tissues with distinct functional properties. FN is found in most ECMs but it is 
especially abundant during embryogenesis and in the provisional matrix of injured tissue 
orchestrating the assembly of many other ECM proteins (Magnusson and Mosher 1998). It 
is also an important adhesion molecule for various cell types. Collagens are the most 
abundant structural elements in adult tissues providing them tensile strength. Collagen 
fibrils can be arranged in different three dimensional arrays: they appear as parallel 
bundles in tendons and ligaments, orthogonal lattices in the cornea and concentric weaves 
in bone (Hulmes 2002; Canty and Kadler 2005). Elastic fibers are able to recoil after 
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transient stretching and they are found in tissues such as skin, blood vessels and lung 
where strength and elasticity are needed (Mecham 1991). 
1.1.1.2 Basement membrane 
Basement membranes (BMs) are specialized forms of ECM with thin, sheet-like structure. 
They are closely associated with epithelial or endothelial cells, muscle fibers, adipocytes 
and peripheral nerves. BMs provide cells with structural support and regulate cell polarity. 
They separate tissues into different compartments and act as molecular filters. In addition, 
BMs regulate cell behavior through interactions between cell surface receptors and ECM 
molecules (Kalluri 2003). The major constituent of BMs is type IV collagen, and other 
main elements include laminin, heparan sulphate PGs (HSPGs) and nidogen/entactin. 
There are also small amounts of other components including fibulins, type XV and XVIII 
collagens and SPARC/osteopontin. The molecular composition of BMs is not uniform 
throughout the body but displays organ-specific differences. For example, type IV 
collagen, laminin and PGs exist in several isoforms whose expression patterns vary in 
different organs.  
Laminin and type IV collagen are capable of initiating the self-assembly of BM 
molecules into sheet-like structures. Laminin is a centerpiece of the structure deposited 
first on the cell surface while the subsequent assembly of type IV collagen provides highly 
crosslinked scaffold for the BM (Timpl 1996; Kalluri 2003). Collagen IV is a member of 
collagen family of trimeric protein consisting of three α-chains. There are six genetically 
different α-chains of type IV collagen and they form three triple helical protomers with 
different chain compositions (Hudson et al. 2003). The expression patterns of the 
protomers differ depending on the developmental stage and tissue. Laminins, which are 
also trimers, consist of α, β and γ chains which give rise to at least 12 different laminin 
isoforms (Timpl 1996). They form networks of mainly noncovalent nature. The formation 
of the connected laminin and collagen IV networks is mediated by nidogen and promoted 
by complex interactions between various BM molecules and also via interactions with cell 
surface receptors (Kalluri 2003). 
 
1.1.2. Collagens 
1.1.2.1 Collagens are a large family of ECM proteins 
Collagens are the most abundant proteins in human body. They are homo- or heterodimers 
of three polypeptides called α-chains. Total of 42 different α-chains exist in vertebrates 
which can form at least 28 types of collagen molecules (Myllyharju and Kivirikko 2004; 
Kadler et al. 2007). The α-chains typically have repeating Gly-X-Y sequences which form 
so called collagenous domains (COL) where the glycine residue is essential for the coiled-
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coil structure. X and Y positions can hold any other amino acid but are often occupied by 
proline and 4-hydroxyproline the latter providing stability for the triple helix. In addition, 
all collagens have also non-collagenous (NC) domains which can be even more abundant 
in certain collagens than the COL domains. The superfamily of collagens is thus very 
heterogeneous and it is further dived into several subfamilies based on their ability to form 
different supramolecular assemblies or other properties. The collagens are designated with 
upper case and the subfamilies with lower case Roman numerals, respectively. 
Fibril-forming collagens (i) are important in providing tissues with tensile strength. 
They are a rather homogeneous group that includes collagen types I, II, III, V, XI, XXIV 
and XXVII of which type I collagen is the most abundant and a classical example of a 
fibrillar collagen (Myllyharju and Kivirikko 2004; Kadler et al. 2007).  The group of 
network forming collagens (ii) consists of collagen types IV, VIII and X of which type IV 
is an important component of BMs functioning as a molecular filter. Collagen type VIII is 
found in Descemet’s membranes and vascular subendothelial matrices and type X in 
hypertrophic cartilage. Collagens of types IX, XII, XIV, XVI and XIX-XXII comprise a 
family of fibril-associated collagens (iii) with interrupted triple helices (FACITs) because 
of their structure and presence on the surface of collagen fibrils. The beaded-filament-
forming collagens (iv) are found in microfibrils and include collagen types VI, XXVI and 
XXVIII. Type VII collagen is present in dermal-epidermal junction attaching BM and 
epithelia to the stroma and is thus called anchoring fibril type of collagen (v). 
Transmembrane collagens (XIII, XVII, XXIII and XXV)(vi) have short cytosolic domains 
and large extracellular domains which have adhesive functions. Collagens XV and XIII 
(vii) are sources of biologically active fragments endostatin and restin, respectively, which 
inhibit endothelial cell migration and angiogenesis. 
Some collagen types such as I, III, V, VI, XII and XIV are found in many types of 
ECM whereas the distribution of certain collagens is very restricted (Myllyharju and 
Kivirikko 2004; Canty and Kadler 2005).  In addition to subfamilies mentioned above, 
there are several COL domains containing proteins that are not classified as collagens, 
such as a subcomponent of C1q of complement, many collectins and some ficolins and 
macrophage receptors, all of which function in immune system. Further, adiponectin, 
acetylcholinesterase, ectodysplasin and two EMILINs also have COL domains.  
The importance of collagen types of ECM proteins is emphasized by the fact that they 
are evolutionarily conserved: most invertebrates have examples of fibrillar and BM 
collagens (Kadler et al. 1996; Huxley-Jones et al. 2007). Moreover, mutations in the genes 
encoding collagens cause a variety of human diseases that include osteogenesis 
imperfecta, chondrodysplasias, various types of Ehlers-Danlos syndrome, arterial and 
intracranial aneurysms, epidermolysis bullosa, the renal disease known as Alport 
syndrome and others (Myllyharju and Kivirikko 2004). 
1.1.2.2 Collagen assembly 
Collagens are synthesized as soluble precursors, procollagens, which undergo extensive 
posttranslational modifications assisted by a number of molecular chaperones and 
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enzymes (Hulmes 2002; Canty and Kadler 2005). The C-terminal propeptide directs the 
association between the three α-chains during assembly in the endoplasmic reticulum 
(ER). The C-propeptide also confers to the high solubility of the procollagen and thus 
prevents too early fibril formation. The N-propeptide affects the diameter of the forming 
fibrils. The N- and C-terminal propeptides are cleaved by specific proteinases during or 
following the secretion of the procollagen molecule. Covalent crosslinks are finally 
formed within and between triple-helical collagen molecules in the growing fibril. 
Purified collagen molecules can self-assemble into fibers in cell-free systems in vitro 
(Kadler et al. 1996). However, the in vivo situation is much more complex as collagens 
interact with other types of collagens and, in addition, with a number of other proteins 
(Kadler et al. 2008). A growing body of evidence suggests that FN and integrins are 
essential for collagen fibril formation (Velling et al. 2002; Li et al. 2003). Inhibition of 
either FN assembly or the function of certain integrins inhibits collagen fiber assembly. 
However, the mechanism how FN and integrins catalyze the fibrillogenesis of collagen is 
not known. Some minor collagens have been suggested to function as nucleators of the 
process. For example, type V collagen, which is codistributed with type I collagen, is 
essential for the assembly of collagen I fibrils in vivo (Wenstrup et al. 2004). Mouse 
embryos lacking collagen V die of cardiovascular failure likely due to the lack of collagen 
fibrils in the mesenchyme. Collagen XI is structurally homologous to collagen V and 
associates with collagens II and IX in cartilage where it is suggested to function as a 
nucleator of the assembly of thin fibers (Kadler et al. 2008). In addition, several other 
molecules, such as decorin, fibromodulin, lumican, perlecan, biglycan and tenascin-C, 
have been shown to affect the formation of collagen fibers (Canty and Kadler 2005; 
Kadler et al. 2008). 
1.1.3 Fibronectin 
1.1.3.1 Fibronectin is a large glycoprotein of the provisional matrix and blood plasma 
Fibronectin (FN) is a large 250 kDa glycoprotein that was first identified from blood 
plasma and on the surface of fibroblasts (Ruoslahti and Vaheri 1974). It is an abundant 
fibrillar component of provisional matrix but it is also found in most interstitial matrices 
and BM (Magnusson and Mosher 1998). Soluble plasma FN is synthesized by hepatocytes 
in the liver whereas in tissues FN is secreted locally by a number of cell types. The 
fundamental role of FN in the ECM was observed by analysis of the knock-out mouse 
which dies at day 8.5 of embryonic development (George et al. 1993). The embryos have 
defects in vascular development, neural tubes and mesodermally derived tissues. 
FN is synthesized as a soluble disulphide-bonded dimer. Both subunits consist of type 
I, II and III repeats and a variable sequence (Magnusson and Mosher 1998). Two of the 
type III repeats are subject to alternative splicing and are absent in plasma FN. The 
variable region can also be spliced out. Different regions confer different properties of 
which the most important is the Arg-Gly-Asp (RGD) sequence in the III10 repeat which 
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mediates the integrin binding to FN (Pierschbacher and Ruoslahti 1984; Pytela et al. 
1985). In addition to integrin receptors, FN harbors binding sites for several other 
molecules including fibrin, collagen, heparin and PGs (Ruoslahti et al. 1982). 
1.1.3.2 Assembly of fibronectin 
FN matrix assembly is a stepwise cell-mediated process (Magnusson and Mosher 1998; 
Wierzbicka-Patynowski and Schwarzbauer 2003; Mao and Schwarzbauer 2005). First the 
secreted soluble FN binds to cell surface primarily via α5β1 integrin although other 
integrins can substitute for it under some conditions. As FN is a dimeric ligand this 
engagement induces integrin clustering and local accumulation of FN which, in turn, 
promotes FN organization into short fibrils. The interactions between the cytoplasmic 
domains of integrins and the actin cytoskeleton are essential for FN assembly. Several 
signaling molecules are recruited to these sites and lead to generation of contractile forces 
that presumably stretch the FN molecules exposing intermolecular interaction sites and 
thus promoting fibril formation. As the fibrils grow soluble FN is also recruited into the 
fibrils through FN-FN interactions in an integrin-independent manner. The extension of 
FN requires disruption of interdomain interactions but the mechanism is poorly 
understood. In addition to integrins, there are other cell-surface or transmembrane 
molecules that affect FN assembly: syndecan-4 and transglutaminase promote FN 
assembly via co-operation with the α5β1 integrin (Wierzbicka-Patynowski and 
Schwarzbauer 2003; Akimov and Belkin 2001). The urokinase receptor for plasminogen 
activator (uPAR) modulates FN assembly by regulating the activation of the α5β1 integrin 
(Monaghan et al. 2004). 
Even though the mature FN matrix is relatively stable it is not a static structure. Cell 
movements and detachment affect the length and shape of FN fibrils. Furthermore, 
continuous polymerization of FN is critical for the maintenance of cell surface FN fibrils 
and for the deposition of other ECM molecules such as type I collagen and 
thrombospondin (Sottile and Hocking 2002).    
1.1.4 Elastic fibers 
1.1.4.1 Elastic fibers are assemblies of elastin and microfibrils  
Elastin is a major component of elastic fibers that are found virtually in all mammalian 
connective tissues (Mecham 1991; Kielty et al. 2002). The unique elastomeric properties 
of elastin provide tissues with reversible deformability which is of special importance in 
arterial vessels, lungs and skin. Elastin fibers are rubber-like polymers capable of being 
rapidly stretched to two to three times their resting length. After release of tension they are 
passively recoiled to the original size. For example, this feature allows the alveolar 
 
 
 
 
16
expansion and recoil during breathing. The architecture of the elastic fibers varies in 
different tissues reflecting tissue specific functions. 
Elastic fibers consist of two morphologically distinct components: an inner core of 
insoluble amorphous appearing elastin and an outer microfibrillar shell (Mecham 1991; 
Kielty et al. 2002). Elastin is synthesized as a soluble ~70 kDa precursor, tropoelastin, 
which, in contrast to collagens, undergoes only minor posttranslational modifications. The 
polymeric, mature elastin is one of the most insoluble proteins in the body and very 
resistant to the extreme conditions used to isolate other ECM proteins. It is also very 
stable under physiological conditions the halftime approaching the lifetime of an 
organism. Mature elastin has a high content of non-polar amino acids and is thus 
extremely hydrophobic. 
Microfibrils are 10-12 nm fibrillar assemblies mainly composed of fibrillins (Kielty et 
al. 2002). They act as structural scaffold for tropoelastin deposition but are also abundant 
in connective tissues devoid of elastin.  There are three different fibrillins, 1-3 (Sakai et al. 
1986; Zhang et al. 1994; Nagase et al. 2001), and they are large (~350 kDa) glycoproteins 
with long stacks of EGF-like repeats and several cysteine-rich domains typical for LTBP-
fibrillin superfamily of proteins (see also 1.3.2 Fibrillins). Fibrillin-2 is expressed during 
early development before the appearance of fibrillin-1. Later, fibrillin-1 is more abundant 
and is expressed in various tissues. 
In addition to elastin and fibrillins, there are several other proteins associated with 
elastic fibers. Microfibril-associated glycoprotein (MAGP) -1 is widely distributed 
associating with most microfibrils and is suggested to be an integral component of 
microfibrils (Gibson et al. 1989; Trask et al. 2000a). The tissue localization of the related 
MAGP-2 is more restricted (Gibson et al. 1998). Latent TGF-β binding proteins (see also 
section 1.3.2 LTBPs and (Hyytiäinen et al. 2004)) belong to the same superfamily with 
fibrillins, and LTBPs -1, -2 and -4 interact with one or more fibrillin (Isogai et al. 2003; 
Hirani et al. 2007; Ono et al. 2009). Fibulins -1, -2, -4 and -5, in turn, bind tropoelastin 
(Timpl et al. 2003; McLaughlin et al. 2006). EMILINs -1 and -2 localize to elastin fibers 
and at least EMILIN-1 binds to elastin (Doliana et al. 1999; Doliana et al. 2001). Several 
PGs, such as decorin, biglycan and versican have been detected in elastic fibers and may 
contribute to their integration into surrounding ECM (Kielty et al. 2002).  
1.1.4.2 Assembly of microfibrils and elastic fibers 
The microfibrillar template is formed first and determines the localization and morphology 
of the elastin fibers (Mecham 1991; Kielty et al. 2002). Microfibrils appear as beads-on-
string-like structures when visualized by various microscopic techniques. Most of current 
knowledge on the assembly of microfibrils is limited to fibrillin-1. The assembly of the 
fibrillin-1 fibrils is at least partially mediated by cells and starts in the secretory pathway 
by C-terminal processing of profibrillin by a furin convertase (Ritty et al. 1999; 
Raghunath et al. 1999). Removal of the C-terminus is needed for the ECM deposition. 
This is followed by rapid formation of N-terminal intermolecular disulphide bonds which 
confer to the fiber insolubility (Trask et al. 1999; Reinhardt et al. 2000). The cross-linking 
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takes place either inside the cell or shortly after secretion. The organization of fibrillin-1 
into microfibrils requires the multimerization of the C-terminus into the bead-like 
structures which then allows the self-interaction of  the N- and C-termini (Hubmacher et 
al. 2008).  
After the formation of the microfibril scaffold the tropoelastin is thought to be 
deposited onto it (Mecham 1991). This model is supported by the observed ability of 
tropoelastin to bind fibrillin-1 and -2 (Trask et al. 2000b). Next the tropoelastin undergoes 
coacervation (self-aggregation) and becomes crosslinked by lysyl oxidase.  
The surrounding ECM and many interacting proteins may affect the assembly of 
microfibrils and elastic fibers as well as their commitment to distinct ECM sites. For 
example FN assembly is required for the deposition of fibrillin-1 (Kinsey et al. 2008). 
Fibrillins -1 and -2 contain heparin binding sites that are important for matrix association 
(Ritty et al. 2003), and heparin can compete with tropoelastin for binding to fibrillin-1 
(Cain et al. 2005). Furthermore, fibulins-4 and fibulin-5 are critical for the maturation of 
elastic fibers via interactions with tropoelastin and fibrillin-1 (McLaughlin et al. 2006; 
Nakamura et al. 2002; Freeman et al. 2005; Zheng et al. 2007; Choudhury et al. 2009). 
EMILIN-1 deficiency disrupts the elastin core without affecting microfibrils (Zanetti et al. 
2004). MAGP-1 is directly involved in elastin fiber assembly and MAGP-2 is able to 
stimulate it (Brown-Augsburger et al. 1996; Lemaire et al. 2007).   
1.1.5 Proteoglycans 
Proteoglycans (PGs) are a diverse group of molecules which are classified after their 
major constituents, sulphated sugar chains, also called glycosaminoglycans (GAGs) 
(Ruoslahti 1988; Hardingham and Fosang 1992). GAGs, which often account for more 
than 80% of the mass of a PG, are attached to the smaller protein core. The sugar side 
chains vary both in structure and in size, and also the core proteins are extremely diverse 
depending on the cell type they are produced by. PGs are highly hydrophilic and bind 
large amount water occupying a lot of space thus providing tissues with amorphous 
ground substance. They also interact with various other molecules affecting many cellular 
functions such as ECM assembly, morphogenesis, cell growth and differentiation, 
tumorigenesis and modulation of growth factor functions. PGs can be divided into three 
groups based on the structure of the GAGs they carry: i) chondroitin/dermatan sulfate PGs 
(CSPGs/DSPGs), ii) heparan sulfate PGs (HSPG) and iii) keratan sulfate PGs (KSPGs) 
(Gesslbauer et al. 2007). All three types of GAGs are strongly negatively charged, and the 
interactions between PGs and other molecules are ionic in nature. The core proteins of 
PGs include perlecan, agrin and bamacan present in BM; versican, decorin, and biglycan 
mainly found in skin; and aggrecan, neurocan and brevican of which aggrecan is abundant 
in cartilage and neurocan is found in brain (Gesslbauer et al. 2007; Iozzo 1998). 
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1.1.6 Remodeling of ECM 
Cells need to respond to environmental stimuli for example during embryogenesis, 
wound healing as well as under pathological conditions (Streuli 1999). The adaptation 
leads to temporal changes in the composition of the ECM. Moreover, the proteolysis of 
ECM molecules exposes previously unavailable sites for cell surface receptors or releases 
growth factors and other biologically active molecules which affect cell behavior. The 
balance between ECM synthesis and degradation is important and is shifted towards 
accumulation of ECM proteins during fibrosis and scarring. A shift towards excessive 
remodeling is seen in arthritis and tumor development (Tlsty and Coussens 2006). During 
early development the remodeling events are required for the differentiation of diverse cell 
types derived from primitive epithelium (Streuli 1999). In the adult, angiogenesis and 
wound healing as well as uterine and mammary gland changes during the menstrual cycle 
and pregnancy are dependent on ECM remodeling. There are numerous enzymes involved 
in these processes including families of serine proteases and metalloproteases.  
Enzymes of the plasmin/uPA system are serine proteases which are especially 
important during wound healing. Thrombin cleaves fibrinogen to form fibrin which forms 
the fibrin clot after wounding (Toriseva and Kähäri 2009). Plasmin has a key role in 
dissolving the fibrin clot to facilitate the migration of the keratinocytes in the healing 
wound. It is abundantly present in blood plasma as a precursor, plasminogen, which is 
activated by plasminogen activators (uPA/tPA), which, in turn, are inhibited by 
plasminogen activator inhibitors (PAI-1 and -2) (Qiu et al. 2007; Andreasen et al. 2000). 
uPA can be specifically targeted to the cell membrane via interaction with its receptor, 
uPAR, to regulate cell migration and invasion. Plasmin and uPA are involved in digesting 
FN and laminin, and regulating the activity of coagulation factors. They can also activate 
several MMPs and growth factors such as hepatocyte growth factor and TGF-β.  
MMPs are a family of 23 highly homologous, mainly secreted or plasma membrane-
associated proteinases that require a zinc ion for their catalytic activity (Nagase et al. 
2006). Together they can digest virtually all ECM molecules and, in addition, many latent 
growth factors and cytokines, cell surface receptors, adhesion proteins and other pro-
proteinases and proteinase inhibitors. For example, MMPs contribute to vascular 
remodeling by degrading the matrix proteins as well as processing vascular endothelial 
growth factor (VEGF), an important initiator of angiogenesis (Page-McCaw et al. 2007). 
MMPs are divided into subgroups based on their substrate preferences and domain 
organization: collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs 
(MT-MMPs) and a group of other MMPs (Nagase et al. 2006). All MMPs have a 
prodomain that maintains the enzyme in inactive form, and a catalytic domain which 
interacts with the prodomain through the zinc ion. The hemopexin domain participates in 
determining substrate specificity and mediates interactions with MMP inhibitors or 
between two MT-MMPs. Through complex formation of MMPs with ECM substrates and 
their cell surface receptors the proteolytic activity can be restricted for example to the 
leading edge of the migrating cell. The activity of MMPs is regulated by α2-
macroglobulin and related proteins present in blood plasma and tissue inhibitors of 
metalloproteinases (TIMPs), which display different specificities for individual MMPs. 
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Roles for several MMPs and their inhibitors have been implicated in different phases of 
wound healing (Toriseva and Kähäri 2009). MMPs -2, -9, -13 and -14 (MT1-MMP) are 
involved in bone development, fracture healing and bone remodeling and MMPs -2 and -3 
are important for the morphogenesis of the mammary gland (Page-McCaw et al. 2007). 
Interestingly, among the numerous mmp knockout mice animals with disrupted MT1-
MMP exhibit the only lethal phenotype. They suffer from skeletal remodeling defects, 
arthritis, osteopenia and angiogenic defects (Holmbeck et al. 1999; Zhou et al. 2000). The 
condition leads to death at 3-12 weeks.   
A disintegrin and metalloproteinase family (ADAMs) and ADAM with 
thrombospondin motifs family (ADAMTSs) resemble MMPs as they also have zinc 
binding motif and are inhibited by TIMPs (Huovila et al. 2005). ADAMs generally exist 
as membrane bound and in a few cases as soluble forms and shed the extracellular 
domains of several membrane-bound molecules including growth factors, cytokines, 
adhesion proteins and receptors. In addition, they can also cleave and remodel components 
of the ECM. The disintegrin motifs of ADAMs mediate their interactions with several 
integrin receptors. ADAMTS have thrombospondin-like modules replacing the 
transmembrane and cytoplasmic domains and are thus soluble proteases (Porter et al. 
2005). In contrast to both MMPs and ADAMs, some of the ADAMTSs associate with the 
ECM. ADAMTSs are involved in blood coagulation homeostasis, regulation of 
angiogenesis and processing of collagens. Their substrates include von Willebrand factor, 
aggrecan, versican and pro-collagens I, II and III.    
1.1.7 Role of ECM in cancer 
Uncontrolled and invasive growth typical for cancer does not solely rely on mutations 
in oncogenes and/or tumor suppressor genes (Tlsty and Coussens 2006; Bhowmick et al. 
2004; Sund and Kalluri 2009). Instead, the reciprocal interactions between cancer cells, 
stromal cells as well as soluble and insoluble components of the surrounding ECM are 
essential for invasive growth. Fibroblasts are the predominant cells in the stroma and 
regulate the composition of the ECM in an organ-specific manner. In tumors they display 
unique and dynamically changing phenotypes and are usually referred as cancer (or 
carcinoma) -associated fibroblasts (CAFs) or myofibroblasts. Acquired expression of α-
smooth muscle actin, vimentin, tenascin and desmin is a typical feature of these cells. 
Genetically altered neoplastic cells can induce the normal fibroblasts to become CAFs or 
myofibroblasts. Vice versa, inherited or acquired mutations in stromal fibroblasts may 
precede the neoplastic transformation of epithelial cells. 
The architecture of the tumor-associated stroma is markedly different from the pre-
existing stroma of healthy tissue. While the turnover of collagens is slow under normal 
conditions the metabolism of type I collagen is increased in neoplastic tissues and the 
newly synthesized collagen fibers are disorganized (Tlsty and Coussens 2006). This may 
promote angiogenesis necessary for tumor development as small blood vessels and 
capillaries are often abundant in tumor stroma and, moreover, high vasculature in the 
primary tumor indicates poor prognosis (Carmeliet and Jain 2000). The importance of 
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microenvironment permissive for tumor growth is emphasized by existence of in situ 
cancers which never invade (Folkman and Kalluri 2004). The dormancy of such tumors is 
thought to be due to the angiogenic defense of the host which includes factors such as 
thrombospondin, tumstatin and endostatin. In addition to regulation of angiogenesis, the 
altered structure of the stroma may also affect the availability of various mitogenic growth 
factors and thus promote tumor growth. In advanced cancer the establishment of 
metastases is also dependent on suitable microenvironment (Sund and Kalluri 2009). 
Carcinoma, a malignant tumor arising from the epithelium, is the most common type 
of human cancer. Polarized three-dimensional structure is important for epithelial cells and 
their impaired interactions with the ECM may lead to the development of carcinoma 
(Bhowmick et al. 2004). Normal tissue architecture is thus an efficient inhibitor of 
tumorigenesis. Normal fibroblasts may prevent epithelium from becoming tumorigenic, 
whereas the accumulation of myofibroblasts leads to epithelial hyperproliferation and 
resistance to apoptosis (De Wever et al. 2008). Cancer cells are able to recruit 
myofibroblasts and induce their differentiation, proliferation and production of 
proinvasive signals. The soluble mediators secreted by myofibroblasts or CAFs include 
various cytokines, such as TGF-β and VEGF, and matrix remodeling enzymes.  
Cancer can be described as a wound that does not heal. In wounded or injured tissue 
the damaged cells are cleared via induction of cell death pathways while cell proliferation 
and matrix production are enhanced to regenerate the tissue or close the wound (Tlsty and 
Coussens 2006). In cancer, the proliferation is sustained and the malignant cells have 
acquired the ability to escape apoptosis. Infiltration of inflammatory cells, namely 
macrophages, is an important phenomenon during wound healing. Macrophages are also 
present in tumor stroma where they may influence the ECM remodeling and facilitate 
invasion. Accordingly, chronic inflammation predisposes to various cancers. On the other 
hand, recruitment of adaptive inflammatory cells, e.g. B and T lymphocytes, may also 
restrict tumor growth.  
MMPs can regulate tumorigenesis in various ways (Folgueras et al. 2004).  Their 
expression or activity is elevated in most cancers and correlates with poor prognosis. As 
MMPs are able to degrade virtually all ECM components they clear the path for cancer 
cell invasion into surrounding stroma and into blood vessels. In addition, MMPs can 
modulate tumor angiogenesis, the immune functions and apoptotic processes by activating 
or releasing growth factors from the ECM reservoir or from plasma membrane 
association. However, MMPs can also release anti-angiogenic/anti-tumorigenic ECM 
fragments such as angiostatin, endostatin (fragment of collagen XVIII), restin (fragment of 
collagen XV) and fragments of collagen IV, arrestin, canstatin and tumstatin. Thus, the 
role of the proteolytic system in tumorigenesis is very complex.    
1.2 Cell adhesion 
The attachment of cells to each other and to the surrounding ECM is crucial for the 
formation and maintenance of tissue architecture. These interactions fundamentally 
regulate cell functions and phenotypes. There are variety of adhesion mechanisms utilized 
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by cells but often the processes and molecular components are similar from the 
morphogenesis throughout the life of an organism (Gumbiner 1996). The adhesive units 
consist of many types of proteins: ECM proteins, cell adhesion molecules/receptors, and 
the cytoplasmic plaque/peripheral membrane proteins. The cell adhesion receptors are 
often transmembrane proteins that mediate cell-cell or cell-ECM adhesion and include 
members of cadherin, immunoglobulin, selectin, integrin and PG superfamilies. On the 
cytoplasmic site of adhesive structures there are a number of molecules which participate 
in signal transduction or organization of the cytoskeleton (Zamir and Geiger 2001).  
1.2.1 Cell-Cell contacts 
 Stable connections between the cells are required for the proper functions of tissues and 
organs. The most widespread types of adhesion contacts include adherens junctions, 
desmosomes and tight junctions (Gumbiner 1996). 
Adheres junctions are formed by homophilic interactions between molecules of 
cadherin family (Gumbiner 1996). They are transmembrane proteins and highly expressed 
in various solid tissues. Widely studied example is E-cadherin which mediates stable 
adhesion between epithelial cells. Loss of its functions can not be compensated by other 
adhesion mechanisms and is associated with increased invasiveness of cells in culture and 
certain tumors. Adhesive function of cadherins requires interactions with cytoplasmic 
plaque proteins such as α- and β-catenins, and actin cytoskeleton. The adherens junctions 
between epithelial cells and associated actin filament bundles are analogous to focal 
adhesions at sites of integrin-ECM contacts and may provide resistance to contractile 
forces for example in the epithelium of digestive tract. 
Desmosomes are sites of strong adhesion and anchored to intermediate filaments (Yin 
and Green 2004). They consist of proteins which fall into three distinct groups: proteins of 
cadherin superfamily, armadillo proteins and plakins. Desmogleins and desmocollins are 
desmosomal cadherins whose cytoplasmic tails associate with plakoglobins and 
plakophilins (the armadillo proteins). Desmoplakin interacts with plakophilin and anchors 
the multiprotein complex to the intermediate filaments. The desmosomes are especially 
abundant in epidermis and disruption of their function leads to epithelial blistering and 
fragility as observed in many autoimmune diseases. 
The main function of tight junctions is to form selective permeability barriers in 
epithelial and endothelial tissues (Kim 1995). They prevent passive diffusion of molecules 
across the paracellular space but allow passing of selected molecules or cells. Tight 
junctions separate the apical and basolateral compartments of cells and are the basis for 
cell polarity. The barrier strand is formed by integral membrane proteins such as 
occluding, claudins and tricellulin (Fanning and Anderson 2009). Cytoplasmic zonula 
occludens proteins, ZO-1 and ZO-2 are required for the assembly of tight junctions. ZO 
proteins mediate the association of tight junctions with cytoskeleton through binding of F-
actin and other proteins involved in the regulation of actin dynamics.  
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1.2.2 Cell-ECM communication 
The interactions between cells and ECM determine the tissue specific functions and 
influence gene expression (Nelson and Bissell 2006). The majority of differentiated cells 
retain certain degree of plasticity to be able to respond to environmental signals and as a 
result, they may even change their phenotype. The response of a cell to growth factor 
signals can be regulated by the surrounding ECM. For example, collaboration between 
collagen I and platelet derived growth factor –BB regulates human dermal fibroblast 
migration (Li et al. 2004). Further, hepatocyte growth factor induces tube formation of 
kidney epithelial cells only inside the collagen matrix. The importance of cell-ECM 
communication in directing tissue specificity is emphasized by the fact that many 
invertebrates have homologs of ECM proteins and integrins.  
1.2.2.1 Integrins 
Integrins are the major ECM receptors.  They are heterodimeric transmembrane receptors 
consisting of α and β subunits (Hynes 2002). They mediate cell-matrix and certain cell-
cell interactions and play important roles in many biological processes such as wound 
healing, maintenance of tissue integrity, cell growth and survival. Integrins participate also 
in various pathological conditions like inflammation and invasion of cancer cells. 
Currently 18 α and 8 β subunits are known and they can form 24 αβ heterodimers with 
wide but tissue specific distribution and distinct although partially overlapping ligand 
binding preferences (Heino 2000; Hynes 2002). A simplified illustration of the receptors 
grouped by their ligand specificities is presented in Fig. 1.  
 
Figure 1. Integrin receptors. Adapted from (Hynes 2002). 
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Both α and β subunits contribute to ligand recognition. Ligands for integrin receptors 
are typically ECM proteins and the short intracellular tail of integrin is anchored to the 
actin cytoskeleton through proteins like talin, paxillin and vinculin (Zamir and Geiger 
2001). Normally most integrins are present on the cell membrane in inactive, non-ligand 
binding state. The cytoplasmic tails of α and β subunit can interact and control the 
activation status. The activation can be regulated for example by growth factors and 
integrin ligands.  
Integrin receptors lack intrinsic enzymatic activity but the cytoplasmic domains are a 
site of accumulation of many signaling molecules such as Src-type kinases and Src 
substrates (Zamir and Geiger 2001). In addition, there are proteins that interact with the 
transmembrane part of an integrin like adaptor protein caveolin. Interactions between cells 
and ECM are both dynamic and reciprocal. Through the multiple interactions integrins 
transmit signals from the extracellular adhesion site into the cell and vice versa. Fig. 2 
illustrates the linkage between ECM and cytoskeleton provided by integrins and a number 
of cytosolic proteins. 
  
 
Figure 2. Integrins link the ECM to the actin cytoskeleton. 
1.2.2.2 HSPGs on the cell surface 
All adherent cell lines carry HSPGs on their surfaces where they modulate the recognition 
of a variety of ECM ligands by forming complexes with them (Bernfield et al. 1999; Park 
et al. 2000).  The groups of syndecans and glypicans account for the majority of cell 
surface HSPGs. Syndecans are extended transmembrane proteins with large ectodomain 
and short cytoplasmic tail whereas glypicans are covalently linked to plasma membrane by 
glycosylphosphatidylinositol (GPI) anchor. HS chains are bound by numerous ECM 
proteins, proteases and their inhibitors, growth factors and their binding proteins as well as 
cytokines, chemokines and even some pathogens. The complex formation can result in 
either stimulatory or inhibitory effects often depending on the concentrations of binding 
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partners. Despite the diversity and abundance of ligands, the HSPG mediated interactions 
are not nonspecific but depend on specific HS sequences. HSPGs can also function as co-
receptors for growth factors. For example, syndecan-1, the predominant HSPG on 
mammary epithelial cell, is a co-receptor for FGF receptor I. 
1.3 Transforming growth factor β 
Transforming growth factor -β (TGF-β) is a small dimeric cytokine expressed virtually in 
all tissues during embryonic development. It was originally found from murine sarcoma 
virus transformed fibroblasts as secreted activity that induced non-malignant rat kidney 
cells to grow in soft agar independent on anchorage to substratum (De Larco and Todaro 
1978). Later, the source of the activity was identified as two distinct factors, TGF-α and -
β (Roberts et al. 1982; Anzano et al. 1982) of which TGF-α belongs to the epidermal 
growth factor (EGF) family of growth factors. TGF-β exists as three different isoforms 
TGF-βs 1-3 in mammals, and isoforms found in chicken and Xenopus have been 
suggested as analogs for human TGF-β1 (Massague 1990). Despite the misleading name, 
TGF-βs are expressed by many normal cells and tissues rather than being a special feature 
of transformed cells. TGF-βs belong to a larger superfamily of structurally related 
cytokines which include bone morphogenic proteins (BMPs), growth differentiation 
factors (GDFs) and inhibins/activins (Massague 1990; Kingsley 1994). These factors have 
diverse effects on cell growth, morphology, differentiation and motility and are 
evolutionary conserved from fruit fly to human. 
1.3.1 Secretion and activation of TGF-β 
TGF-β1 is a prototype cytokine of the family. It is secreted as a large precursor molecule 
and its N-terminal propeptide is cleaved by a furin convertase during secretion (Sha et al. 
1989; Dubois et al. 1995). The mature TGF-β is a dimer of 112 amino acid C-terminal 
subunits which are linked together via disulphide bonds. The propeptide remains non-
covalently associated with the growth factor inhibiting its activity and is thus denoted 
latency associated peptide (LAP) (Lawrence et al. 1984; Gentry et al. 1988; Gentry and 
Nash 1990). This complex is called small latent complex (SL-TGF-β). In addition to 
conferring latency, β1-LAP is important for the folding and secretion of TGF-β1 
precursor. In most cells SL-TGF-β is bound to a large glycoprotein, latent TGF-β binding 
protein (LTBP), through disulphide bonds between LAP and LTBP yielding a large latent 
complex (LL-TGF-β)(Saharinen et al. 1999). Some cells, such as glioblastomas and 
osteoblasts, secrete SL-TGF-βs (Olofsson et al. 1992; Dallas et al. 1994) and it can be 
found on the surface of platelets or activated regulatory T-cells (Grainger et al. 1995; 
Nakamura et al. 2004; Andersson et al. 2008). However, it has been found that LTBP 
facilitates the secretion and correct folding of TGF-β (Miyazono et al. 1991). It also 
targets the complex to the ECM forming a reservoir of the growth factor to be readily 
available upon appropriate stimulus (Taipale et al. 1994; Dallas et al. 1995).  
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Mature TGF-β needs to be released from the latent complex in order to bind its cell 
surface receptors and to trigger biological responses. A number of chemical, physical and 
biological mechanisms have been indicated in the activation of TGF-β. Exposure to 
extremes of pH or to urea, as well as heat treatment activates TGF-β in vitro (Lawrence et 
al. 1985; Brown et al. 1990). Proteases, such as plasmin and MMPs -2, -9, and -14 are able 
to activate TGF-β, some of them probably also in vivo (Lyons et al. 1988; Karsdal et al. 
2002; Yu and Stamenkovic 2000). In addition, latent TGF-β can be activated on the 
surface of smooth muscle cells in co-cultures with endothelial cells, presumably by 
plasmin (Sato and Rifkin 1989). Other activators include thrombospondin and integrins 
αvβ6 and αvβ8 (Schultz-Cherry and Murphy-Ullrich 1993; Schultz-Cherry et al. 1994; 
Munger et al. 1999; Mu et al. 2002). Contribution of integrins αvβ3 and αvβ5 to TGF-β 
activity in scleroderma fibroblasts has also been implicated (Asano et al. 2005a; Asano et 
al. 2005b).  
 
 
 
Figure 3. Illustration of the large latent TGF-β complex and activation mechanisms. 
Modified from (Saharinen et al. 1999; Koli et al. 2008a). 
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The integrin-mediated activation of TGF-β may involve generation of intracellular and 
extracellular tension leading to conformational changes in LL-TGF-β as illustrated by the 
ability of the myofibroblast contraction to activate TGF-β1 via integrins but independently 
of proteases (Wipff et al. 2007). This is further supported by the requirement of FN in the 
αvβ6-mediated activation of TGF-β/LTBP-1 complexes (Fontana et al. 2005). By contrast, 
TGF-β1 activation via αvβ8 is dependent on MT1-MMP (Mu et al. 2002). Notably, the 
LAP of TGF-β2 lacks the RGD sequence recognized by integrins and thus cannot be 
activated via these mechanisms (Sheppard 2005). 
Interestingly, the mice with targeted mutation in RGD sequence resulting in impaired 
integrin mediated TGF-β activation have phenotype which very closely resembles that of 
TGF-β1 null mouse (Yang et al. 2007). This would imply that the integrin mediated 
activation mechanisms could predominate in vivo. However, the proteases are important 
regulators of the integrin mediated activation (Mu et al. 2002; Jenkins et al. 2006). In 
addition, a variety of proteases including plasmin, thrombin, elastase, MMP-2 and BMP1 
can liberate latent TGF-β complexes from the ECM (Taipale et al. 1992; Taipale et al. 
1995; Dallas et al. 2002; Ge and Greenspan 2006). Furthermore, the expression of 
truncated form of LTBP-1, which is unable to associate with the ECM, leads to the 
formation of soluble latent TGF-β complexes and increased TGF-β activity (Mazzieri et 
al. 2005). Thus, the proteolytic release of latent complexes from the ECM could be the 
first step in the activation process.  
1.3.2 TGF-β receptors and signaling  
The family of cell surface receptors for TGF-β comprises subfamilies of type I and type II 
receptors, based on structural and functional similarities. Both types are serine/threonine 
transmembrane kinases and they both are essential for TGF-β signaling (Attisano and 
Wrana 1996; Shi and Massague 2003). Only the type II receptors bind free ligands 
whereas type I receptors recognize the conformationally changed ligand bound by type II 
receptors or the receptor-ligand interface. The formed complex is a heterotetramer which 
is bound to the dimeric ligand. Type II receptors phosphorylate the type I receptors on 
multiple serine and threonine residues. The kinase activity of type II receptor is essential 
for TGF-β-signaling and it is not dependent on ligand binding. Five type II receptors and 
seven type I receptors exist in mammals. For TGF-β ligands there is only one type II 
receptor (TβRII), and three distinct type I receptors, ALK1, ALK2 and ALK5/TβRI, of 
which TβRI mediates the majority of TGF-β responses. Other receptors or receptor 
combinations recognize other ligands of the TGF-β superfamily. 
There are also membrane bound TGF-β binding molecules which do not have intrinsic 
kinase activity but contribute to TGF-β signaling as assisting receptors (Massague 1990; 
Massague and Chen 2000). Betaglycan is an abundantly expressed transmembrane PG 
also called type III receptor. It binds all TGF-β isoforms but is especially important in 
presenting TGF-β2 to type II receptor. A related protein endoglin is highly expressed in 
activated endothelial cells and is involved in vascular homeostasis. It is essential during 
angiogenesis as it promotes proliferation and migration of endothelial cells by regulating 
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the balance between ALK1 and ALK5/TβRI signaling (Lebrin et al. 2004). Some GPI-
anchored TGF-β binding proteins have also been identified and suggested to regulate 
TGF-β responses in keratinocytes (Tam et al. 2003).    
 The canonical signaling pathway activated by TGF-β receptors is the Smad pathway 
(Massague 2000; Shi and Massague 2003), which is illustrated in Fig. 4.  The type I 
receptors phosphorylate and thereby activate Smad2 and -3 or Smad1 and -5, depending 
on the receptor complex. These Smads are called receptor activated Smads (R-Smads). 
The access of Smad2 and -3 to TβRI can be facilitated by SARA (the Smad anchor for 
receptor activation) which immobilizes Smad2/3 near the cell surface. The phosphorylated 
R-Smads then form complexes with Co-mediator Smad, Smad4. This heteromeric 
complex translocates into the nucleus where it interacts with transcriptional co-activators 
such as CBP, p300 or ARC105 to regulate the expression of target genes.  Smad6 and -7 
are inhibitory Smads which can bind to the activated type I receptor and inhibit the 
phosphorylation of R-Smads. Smad7 can also recruit Smurf1 (Smad –ubiquitination-
regulatory factor 1) or Smurf2 to the receptor complex and thus target it for degradation 
(Kavsak et al. 2000; Ebisawa et al. 2001). In addition, there are several proteins which can 
interact with Smads and affect the TGF-β response (Derynck and Zhang 2003).  
 
 
Figure 4. TGF-β signaling via Smad2/3. Modified from (Attisano and Wrana 2002) . 
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TGF-β can also activate other pathways including ERK, JNK and p38 mitogen 
activated protein kinase (MAPK) pathways (Derynck and Zhang 2003). Activation of 
small GTPases Rho, Rac and cdc42 and PI3 kinase has also been indicated. Interestingly, 
there is evidence that at least MAPK pathways converge on Smads. The crosstalk between 
different pathways can result in co-operation or the activities may counteract each other. 
For example signaling via GTPases, p38 and Smads have all been indicated during TGF-β 
induced epithelial-to-mesenchymal transition. 
The common mechanisms for ending the Smad signaling are ubiquitination and 
proteasome mediated degradation of R-Smads or their dephosphorylation although the 
phosphatases have not been identified yet (Shi and Massague 2003). Degradation of the 
activated receptor complex by a proteasome also terminates TGF-β signaling. 
1.3.3. TGF-βs have diverse effects on cells 
TGF-β(s) exert three major functions on cells (Massague 1990; Lawrence 1996; 
Roberts 1996a; Letterio and Roberts 1998). Firstly, it inhibits proliferation of many cells 
types, typically of endodermal origin such as endothelial and epithelial cells but also some 
other cell types including keratinocytes. However, it can promote the growth of cells of 
mesenchymal origin such as fibroblasts and smooth muscle cells. The effect often depends 
on the growth factor concentration. Secondly, TGF-β induces the synthesis of many ECM 
components, such as collagen, FN, tenascin, GAGs and PGs. Moreover, it inhibits the 
production of many ECM degrading proteases and induces the expression of protease 
inhibitors, especially plasminogen activator inhibitor -1 (PAI-1) (Laiho et al. 1986). 
Thirdly, TGF-β is a potent suppressor of immune functions. The mechanism acts partly 
via the regulation of immune cell proliferation and differentiation.  
The expression levels of different integrin subunits can be upregulated by TGF-β 
(Heino and Massague 1989). Together with increased amount of ECM components this 
leads to strengthened adhesion of TGF-β treated cells. However, some subunits may be 
strongly downregulated in certain cells. TGF-β can thus alter the repertoire of integrin 
receptors. 
TGF-β is critically involved in wound healing, which is a process of intense 
accumulation and remodeling of the ECM (Massague 1990; Roberts 1996a; Toriseva and 
Kähäri 2009). The platelets are a rich source of TGF-β (Assoian et al. 1983) which is then 
available in the site of injury. It is also produced by cells of all leukocytic lineages such as 
monocytes and macrophages (Letterio and Roberts 1998). TGF-β is a chemoattractant for 
monocytes and fibroblasts and may recruit these cells to the site of wound repair (Wahl et 
al. 1987; Postlethwaite et al. 1987). By inducing the expression of ECM proteins TGF-β 
stimulates the accumulation of granulation tissue.  
Vascular development is also regulated by TGF-β (ten Dijke and Arthur 2007). Low 
concentrations of TGF-β1 promote the proliferation and migration of endothelial cells 
which is required for angiogenesis, whereas high concentrations induce the production of 
ECM proteins typical for mature vessels (Lebrin et al. 2004). Further, TGF-β1 promotes 
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vascular muscularization by stimulating the differentiation of mesenchymal cells into  
SMCs and pericytes (ten Dijke and Arthur 2007).  
TGF-βs 1-3 are highly homologous and often influence the cells in a similar manner in 
vitro. However, in vivo, they have distinct, although partially overlapping, spatial and 
temporal expression patterns and distinguishing features in their promoters indicating 
differential regulation. Mice with disrupted expression of TGF-β1 born as normal but die 
soon after weaning, at 2-3 weeks, due to massive infiltration of immune cells into various 
organs (Shull et al. 1992; Kulkarni et al. 1993). TGF-β2 gene targeted mice have diverse 
developmental defects including cranial, cardiac and lung defects (Sanford et al. 1997) and 
mice deficient for TGF-β3 suffer from cleft palate and abnormal lung development 
leading to death soon after birth (Proetzel et al. 1995). Interestingly, mice that overexpress 
TGF-β1 also die early (Sellheyer et al. 1993) emphasizing the fact that the effects of TGF-
β are not only context but also concentration specific. 
 
1.4 LTBP-fibrillin family 
LTBP-fibrillin family of ECM proteins consists of LTBPs 1-4 (Kanzaki et al. 1990; Tsuji 
et al. 1990; Moren et al. 1994; Yin et al. 1995; Giltay et al. 1997; Saharinen et al. 1998) 
and fibrillins 1-3 (Sakai et al. 1986; Zhang et al. 1994; Nagase et al. 2001). They are often 
localized to long fibrillar structures which are 10-12 nm in diameter and called 
microfibrils (see also 1.1.4.1 Elastic fibers are assemblies of elastin and microfibrils). The 
molecular mass of LTBPs is 120-240 kDa whereas the fibrillins are markedly larger, ~350 
kDa. They are mainly composed of cysteine rich EGF-like repeats with proline or glycine 
rich flanking regions. The unique feature for this protein family is the presence of eight 
cysteine (8-Cys) repeats that have not been detected in any other proteins. EGF-like 
repeats, instead, are found in many ECM and transmembrane proteins including fibulins -
1 and -2, nidogen, and low density lipoprotein receptor, and they act as structural elements 
and mediate protein-protein interactions. LTBPs contain 15-20 and fibrillins 47 EGF-like 
repeats. The majority of these repeats are of calcium binding type but there are a few of 
non-calcium binding repeats. Four 8-Cys domains (including one hybrid domain) are 
present in LTBPs and nine (including two hybrid domains) in fibrillins. The basic domain 
structures are illustrated in Fig. 5. and reviewed in more detail in (Hyytiäinen et al. 2004).   
1.4.1 LTBPs 
LTBPs were first identified as binding proteins for TGF-β. LTBP-1 was isolated from 
platelets (Miyazono et al. 1988). It was characterized as a 125-160 kDa protein that was 
linked by disulfide bonds to the TGF-β1 precursor (named later as LAP) and together with 
non-covalently bound TGF-β1 they formed a 210 kDa latent complex. The cDNA cloning 
revealed that fibroblast LTBP-1 is considerably larger, 170-190 kDa, than platelet derived 
LTBP-1 (Kanzaki et al. 1990). LTBP-1 has been shown to exist as two N-terminally 
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distinct forms, LTBP-1S (the short form) and LTBP1-L (the long form) (Kanzaki et al. 
1990; Tsuji et al. 1990; Olofsson et al. 1995), whose expression is driven by independent 
promoters (Koski et al. 1999). Other, alternatively spliced forms have also been identified 
(Öklü et al. 1998b; Öklü et al. 1998a; Gong et al. 1998; Michel et al. 1998). The N-
terminus of LTBPs is important for the association with the ECM and LTBP-1L appeared 
to be more efficiently bound to the matrix (Olofsson et al. 1995; Öklü et al. 1998a). The 
other splice variants could protect the protein from degradation (Gong et al. 1998; Michel 
et al. 1998). LTBP-1 is expressed almost in all tissues but there are differences in the 
expression pattern of different splice variants (Tsuji et al. 1990; Olofsson et al. 1995; Öklü 
et al. 1998a). The expression of LTBP-1L is mainly detected in the heart, placenta, kidney 
and prostate whereas LTBP-1S is expressed also in the lung, spleen, stomach, ovary, testis 
and skeletal muscle. The cloning of mouse LTBP-1 also revealed several alternatively 
spliced forms with tissue specific expression patterns (Noguera et al. 2003; Weiskirchen et 
al. 2003). In addition, LTBP-1L is the only form expressed in mouse embryos whereas 
LTBP-1S predominates in adults (Weiskirchen et al. 2003).  
 
 
Figure 5. The domain structures of LTBPs and fibrillins. Modified from (Saharinen et al. 
1999). 
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LTBPs -2 and -3 were identified on the basis of sequence similarity to LTBP-1 (Moren 
et al. 1994; Yin et al. 1995). Northern blot hybridization analysis revealed that, like 
LTBP-1, LTBP-2 migrates as two transcripts suggesting possible alternative splicing 
(Moren et al. 1994). It is highly expressed in the lung, and also in the heart, placenta, liver 
and skeletal muscle. The expression in the lung, dermis, perichondrium, arterial vessels, 
epicardium, pericardium and heart valves has been detected during rodent development 
(Fang et al. 1997; Shipley et al. 2000).  
Human LTBP-3 exists as two different forms the longer having an additional EGF-
repeat in the C-terminus (Penttinen et al. 2002). Two splice variants have been 
characterized for the mouse LTBP-3 as well (Yin et al. 1995). LTBP-3 is expressed 
especially in the skeletal muscle, heart, prostate and ovaries and to lesser extent in testis 
and small intestine (Penttinen et al. 2002). It is also expressed in developing bone in 
mouse (Yin et al. 1995).  
LTBP-4 was found by searching homologues for 8-Cys repeats from sequence 
databases (Saharinen et al. 1998). LTBP-4 has also various alternatively spliced forms 
(Saharinen et al. 1998; Koli et al. 2001) of which one lacks the third 8-Cys repeat, a motif 
needed for the complex formation with SL-TGF-β (Koli et al. 2001). LTBP-4 is 
predominantly expressed in the aorta, heart, small intestine, skeletal muscle and ovaries 
(Giltay et al. 1997; Saharinen et al. 1998). The expression of two N-terminally distinct 
LTBP-4 variants, LTBP-4S (short) and -4L (long) is driven by independent promoters and 
gives rise to the tissue-specific expression pattern: both variants are expressed in the heart 
and skeletal muscle whereas LTBP-4L predominates in liver and LTBP-4S in lung as well 
as in small intestine (Kantola et al. 2010). Interestingly, marked differences in the 
secretion and processing of LTBP-4S and -4L were found. LTBP-4L was secreted in 
complex with TGF-β1, whereas the majority of LTBP-4S was secreted in a free form.  
1.4.1.1 LTBPs -1, -3 and -4 are binding proteins for small latent TGF-β 
The major role for LTBP-1 was first identified in the assembly and secretion of latent 
TGF-β1 as the SL-TGF-β was secreted slowly without LTBP (Miyazono et al. 1991).  The 
majority of cells secrete TGF-β1 as large latent complexes (Olofsson et al. 1992; 
Flaumenhaft et al. 1993; Taipale et al. 1994; Taipale et al. 1998), which are targeted to the 
ECM by LTBP (Taipale et al. 1994). The binding site for SL-TGF-β in LTBPs was 
identified as the third 8-Cys repeat (Saharinen et al. 1996; Gleizes et al. 1996). LTBPs -1, 
-3 and -4 associate with SL-TGF-β whereas LTBP-2 does not (Saharinen and Keski-Oja 
2000). In addition, there are differences in the complex formation properties: LTBPs -1 
and -3 associate with the propeptides of all three TGF-β isoforms but LTBP-4 binds only 
TGF-β1-LAP and more weakly than the other LTBPs. Interestingly, LTBPs -1 and -4 are 
secreted also in free forms whereas LTBP-3 seems to require TGF-β for its own secretion 
(Chen et al. 2002; Penttinen et al. 2002).  
The matrix association of LTBPs is predominantly mediated by the N-terminal 
domains (Saharinen et al. 1996; Unsöld et al. 2001; Chen et al. 2007; Kantola et al. 2008). 
Truncated large complexes can be released from the ECM by cleavage of LTBPs by 
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plasmin or other proteases (Taipale et al. 1994; Taipale et al. 1995). The release of latent 
TGF-β complex is suggested as a first step in some activation mechanisms of TGF-β 
(Taipale et al. 1995; Dallas et al. 2002). Antibodies against LTBP-1 inhibit the activation 
of TGF-β by co-cultures of endothelial and smooth muscle cells (Flaumenhaft et al. 1993), 
and integrin αvβ6 mediated activation requires LTBP-1 (Annes et al. 2004) suggesting a 
role for LTBP-1 in the activation process. LTBP-3, in addition to LTBP-1, is important for 
regulation of TGF-β activity during the osteogenic differentiation of mesenchymal stem 
cells in vitro (Koli et al. 2008b). In a mouse model of muscular dystrophy reduced 
proteolytic cleavage of LTBP-4 is associated with reduced TGF-β signaling and less 
severe condition (Heydemann et al. 2009). Moreover, mice, which have mutated TGF-β1 
unable to form complexes with LTBPs, show decreased TGF-β signaling and suffer from 
inflammation and tumors (Yoshinaga et al. 2008). 
Generation of gene targeted mice has revealed the special roles for different LTBP 
isoforms in the regulation of TGF-β: the deletion of LTBP-1L results in congenital heart 
defects (Todorovic et al. 2007). LTBP-3 knockout mice exhibit skeletal abnormalities 
such as cranio-facial defects, osteosclerosis and osteoarthritis (Dabovic et al. 2002). 
LTBP-4S hypomorphic mice suffer from severe pulmonary emphysema and colorectal 
cancer (Sterner-Kock et al. 2002). In addition, null mutations of LTBP-4 in humans result 
in syndrome with severe pulmonary defects and impaired gastrointestinal, musculoskeletal 
and dermal development (Urban et al. 2009). The effects on TGF-β activity are complex 
and context specific. TGF-β activity is dereased in the cardiac outflow track of mice 
deficient for LTBP-1L (Todorovic et al. 2007). The bone phenotype of LTBP-3 knock-out 
mouse is consistent with earlier studies where decreased TGF-β signaling in osteoblasts 
increased the trabecular bone mass (Filvaroff et al. 1999) whereas over-expression of 
TGF-β2 led to osteoporosis (Erlebacher and Derynck 1996). The disruption of LTBP-4S 
function increases TGF-β signaling in the mouse lung in vivo (Dabovic et al. 2009) but 
decreases the amount of active TGF-β secreted by the -/- fibroblasts in culture (Koli et al. 
2004). In the human condition, the lack of LTBP-4 in the ECM results in increased TGF-β 
activity (Urban et al. 2009).  
As LTBPs have only partially overlapping expression patterns and as they bind 
different TGF-β isoforms with different affinities it is possible that they may also 
differentially contribute to the TGF-β activation. At least they regulate the ECM 
localization of and availability of TGF-β. 
LTBPs are often secreted as free forms, in excess to TGF-β implicative of other, 
possibly structural roles for LTBPs in the ECM (Miyazono et al. 1991; Taipale et al. 1994; 
Taipale et al. 1995). In addition, the expression patterns of LTBPs do not always correlate 
with those of TGF-βs. The existence of the LTBP-4 splice variant unable to bind SL-TGF-
β (Koli et al. 2001) further implies that it could have functions not related to TGF-β. 
Indeed, it has recently been suggested to play a role in elastogenesis in the lung (Dabovic 
et al. 2009). Moreover, the predominating isoform in the lung, LTBP-4S, is mainly 
secreted from cells as free form (Kantola et al. 2010). 
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1.4.1.2 LTBP-2 – an exceptional family member 
LTBP-2 is the largest member of the LTBP family. It has a domain structure similar to 
that of other LTBPs, especially to the long form of LTBP-1, but it also contains unique 
regions which make it a close relative of fibrillin-1 (Moren et al. 1994; Gibson et al. 1995; 
Bashir et al. 1996). The important difference to other LTBPs is that the third 8-Cys repeat 
of LTBP-2 lacks two amino acids between the cysteines 6 and 7 compared to 
corresponding repeats of the other LTBPs and can not form disulfide bonds with the LAP 
part of SL-TGF-β (Saharinen and Keski-Oja 2000). Biochemical characterization of 
LTBP-2 revealed that it is a glycosylated, calcium binding protein, which, like LTBP-1, is 
susceptible for proteolytic processing by plasmin and elastase (Hyytiäinen et al. 1998).  
Furthermore, the proteolytic cleavage resulted in the release of LTBP-2 from the ECM of 
fibroblasts. Interestingly, the phenotype of the knock-out mouse is strikingly more severe 
than the phenotypes of other ltbp gene targeted mice.  The LTBP-2 -/- mouse embryo dies 
already before implantation, at E3.5-4.5, suggesting a crucial function for LTBP-2 during 
development (Shipley et al. 2000). The phenotype is not consistent with the mice with 
disrupted function of any of the TGF-β isoforms further emphasizing the function 
independent of TGF-β. Already earlier it was found that the bovine LTBP-2 was strongly 
associated with elastic fibers suggesting a structural role for it in the ECM (Gibson et al. 
1995). It has also much more restricted expression pattern in embryonic mouse tissues 
than the other LTBPs implicative of special functions (Fang et al. 1997). A recent report 
has indicated human ltbp-2 as a candidate gene for bone mineral density variation and 
fracture etiology (Cheung et al. 2008). In addition, the protein levels of LTBP-2 decreased 
during osteogenic differentiation of mesenchymal cells suggestive of involvement in bone 
matrix homeostasis (Koli et al. 2008b). Furthermore, a null mutation in LTBP-2 is 
indicated as one causative factor in primary congenital glaucoma in humans (Ali et al. 
2009). 
1.4.1.3 ECM associations of LTBPs 
All LTBPs are targeted to the ECM after secretion (Taipale et al. 1994; Hyytiäinen et al. 
1998; Koli et al. 2005). LTBP-1 colocalizes with FN and fibrillin-1 in cell cultures 
(Taipale et al. 1996). In vivo, it has been immunolocalized to microfibrillar structures in 
the skin, bone and heart (Raghunath et al. 1998; Dallas et al. 2000; Nakajima et al. 1997), 
and shown to codistribute with fibrillin-1 (Sinha et al. 2002; Isogai et al. 2003). The N-
terminus of LTBP-1 was identified as the site for covalent, transglutaminase mediated 
cross-linking into the matrix (Nunes et al. 1997). Although the major ECM interacting 
sites reside in the N-terminus (Saharinen et al. 1996; Unsöld et al. 2001; Chen et al. 2007), 
the C-terminal motif of LTBP-1 specifically binds to N-terminus of fibrillin-1 (Isogai et 
al. 2003). In addition, the homologous region of fibrillin-2 also interacted with LTBP-1. 
However, LTBP-1 is not strongly cross-linked into microfibrils as it is not detected in 
microfibril extracts. The matrix assembly of LTBP-1 is dependent on FN (Dallas et al. 
2005) and potentially regulated by HSPGs (Chen et al. 2007).  
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During the course of current studies the interaction between LTBP-2 and fibrillin-1 
was discovered (Hirani et al. 2007). Accordingly, they were shown to colocalize in 
developing human aorta. Subsequently it was found that LTBP-2 binds fibulin-5 and 
regulates the assembly of elastic fibers (Hirai et al. 2007). It was suggested to act by 
depositing the tropoelastin preferentially on fibrillin-1 microfibrils. 
LTBPs -3 and -4 associate with fibrillar structures in the fibroblast ECM but they are 
deposited to the matrix considerably later than LTBP-1 (Koli et al. 2005). Analogously to 
LTBP-1, the assembly of LTBP-4 is dependent on FN and the binding is mediated by an 
N-terminal domain of LTBP-4 (Kantola et al. 2008). In addition, the C-terminus of LTBP-
4, but not LTBP-3, interacts with fibrillin-1 similarly to LTBP-1 and LTBP-2 (Isogai et al. 
2003; Hirani et al. 2007). Notably, LTBP-4S seems to be more efficiently incorporated 
into the ECM than LTBP-4L in cell culture (Kantola et al. 2010).The matrix interacting 
domains of LTBP-3 have not been characterized so far. 
1.4.2 Fibrillins 
Fibrillins 1-3 (Sakai et al. 1986; Zhang et al. 1994; Nagase et al. 2001) are the main 
constituents of microfibrils, which are found both as associated with elastin fibers and in 
nonelastic tissues, such as the periodontal ligament and glomerulal mesangium of kidney 
(Gibson et al. 1989; Zhang et al. 1995). By electron microscopy and rotary shadowing the 
microfibrils have been characterized as “beads on a string” structures. The three isoforms 
display spatially and temporally diverse expression patterns. Fibrillin-2 is the 
predominating isoform during mouse embryonic development and is widely expressed by 
a variety of cells in mesenchyme and epithelium (Zhang et al. 1995). Its expression 
decreases rapidly after tissue differentiation whereas the amount of fibrillin-1 gradually 
increases and in the adult it is the major isoform. Exceptionally, in developing large 
vessels and arterioles fibrillin-1 is expressed early and the levels are higher than those of 
fibrillin-2. During human embryonic development fibrillins -1 and -2 display coinciding 
expression in most tissues such as skin, heart and lung but differ in kidney, liver, rib 
anlagen and notochord (Quondamatteo et al. 2002). The expression of fibrillin-3 is largely 
limited to fetal tissues (Corson et al. 2004). As fibrillins -1 and -2, fibrillin-3 is found in a 
variety of connective tissues including perichondrium, periosteum, skeletal muscle, tendon 
and skin. However, in contrast to the other fibrillins, it is absent from the blood vessels of 
lung and is neither detected in the vasculature of other organs where fibrillin-1 is 
abundant. 
Fibrillins are involved in elastogenesis forming the template for tropoelastin deposition 
(Mecham 1991; Kielty et al. 2002)(see also section 1.1.4.2 Assembly of microfibrils and 
elastic fibers). Due to the differing expression patterns, fibrillin-2 has been suggested to 
regulate the early phases of elastogenesis whereas fibrillin-1 provides the elastic fibers 
with force-bearing structural support (Zhang et al. 1995). Special functions for fibrillin-3 
have not been implicated yet. Evidence is accumulating that fibrillins are important 
regulators of tissue homeostasis. Several mutations have been identified in fibrillin-1 that 
cause a pathological human condition called the Marfan syndrome (Dietz et al. 1991; 
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Maslen et al. 1991). The main manifestations affect the skeletal and cardiovascular 
systems.  Gene targeted mice with disrupted function of fibrillin-1 show similar vascular 
phenotype as Marfan patients but normal elastin staining of tissues (Pereira et al. 1997). 
The complete knock-out of fibrillin-1 leads to death soon after birth mainly due to 
ruptured aortic aneurysm and pulmonary defects (Carta et al. 2006). Interestingly, the 
pathology of Marfan syndrome is associated with dysregulation of TGF-β (Neptune et al. 
2003). Moreover, a fragment of fibrillin-1 can compete with LTBP-1 for binding to N-
terminus of fibrillin-1 and subsequently increase TGF-β signaling (Chaudhry et al. 2007). 
Hence, fibrillin-1 may regulate the bioavailability of TGF-β. Mutations in fibrillin-2 lead 
to a connective tissue disorder called congenital contractural arachnodactyly (Maslen et al. 
1991; Putnam et al. 1995). The patients suffer from arachnodactyly, scoliosis and multiple 
congenital contractures. Accordingly, fibrillin-2 null mice are born with contractures of 
joints, which, however, resolve soon after birth (Arteaga-Solis et al. 2001). The 
phenotypes of the gene targeted mice suggest that fibrillins -1 and -2 perform partially 
overlapping functions, and the first proof of that has been obtained from aortic 
development (Carta et al. 2006).  
The last three calcium binding EGF-like repeats in fibrillin-1 are a site for self-
interaction and the C-terminal halves can assemble into multimeric globular structures 
corresponding to the “beads” in the beaded-string structures (Hubmacher et al. 2008). 
Fibrillins 1- and -2 can co-assemble and may be present in the same microfibrils but the 
molecular composition of fibrils depends on tissues and cell types (Charbonneau et al. 
2003). The matrix assembly of fibrillin-1 is dependent on FN (Kinsey et al. 2008) and may 
be regulated by various interacting molecules (see section 1.1.4.2 Assembly of 
microfibrils and elastic fibers).  
Analogously to SL-TGF-β also several BMPs, members of TGF-β superfamily, are 
associated with their prodomains during secretion from cells (Gregory et al. 2005; Sengle 
et al. 2008). These complexes are targeted to the ECM via interaction with fibrillin-1. 
Fibrillins may also mediate cell adhesion via domains recognized by integrins αvβ3, α5β1 
and αvβ6 (Pfaff et al. 1996; Sakamoto et al. 1996; Bax et al. 2003; Jovanovic et al. 2007).  
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2 Aims of the present study 
When this study was initiated it had just been observed that LTBP-2 is unable to bind the 
SL-TGF-β (Saharinen and Keski-Oja 2000). The embryonic lethality of ltbp-2 knockout 
mouse had been published (Shipley et al. 2000). The defects in the implantation of the 
mouse and the classical integrin recognition site, RGD, within LTBP-2 inspired us to 
search for putative roles for LTBP-2 in cell adhesion. In the field of cancer biology, we 
were interested in the roles of LTBPs in the regulation of TGF-β activity. 
 
Specific aims of the study were: 
 
1. To analyze whether LTBP-2 or its fragments have a role in cell adhesion. 
2. To analyze the kinetics and regulation of LTBP-2 secretion and its deposition to ECM. 
3. To elucidate the mechanisms by which TGF-β is released from the matrix of endothelial 
cells. 
4. To investigate whether LTBPs play a role in the targeting and activation of TGF-β in 
mesothelioma. 
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3 Materials and methods 
3.1 Cells and antibodies 
Cell lines used are listed below with their American Type Culture Collection (ATCC, 
Manassas, VA, USA) reference number or reference. 
 
Cell line Description Reference or source 
CCL-137 human embryonic lung fibroblasts ATCC; CCL-137 
HT-1080 human fibrosarcoma cell line ATCC; CCL-121 
CHO chinese hamster ovary ATCC; CCL-61 
Bowes human melanoma cell line ATCC; CCL-9607 
G361 human melanoma cell line ATCC; CRL-1424 
WM 163 human melanoma cell line Wistar melanoma, Wistar Institute, USA 
WM 164 human melanoma cell line Wistar melanoma, Wistar Institute, USA 
WM 165 human melanoma cell line Wistar melanoma, Wistar Institute, USA 
WM 166 human melanoma cell line Wistar melanoma, Wistar Institute, USA 
WM 167 human melanoma cell line Wistar melanoma, Wistar Institute, USA 
HUVEC human umbilical vein endothelial cells Wistar melanoma, Wistar Institute, USA 
MG-63 human osteosarcoma cell line ATCC; CRL-1427 
MEF 
FN+/+ 
mouse embryonic 
fibroblasts, wild type 
Dr. Reinhardt Fässler, Max Planck Institute, of 
Biochemistry, Martinsried, Germany  
MEF     
FN -/- 
mouse embryonic 
fibroblasts, FN deficient Dr. Reinhardt Fässler 
 
Antibodies used are listed below. 
 
Antigen Description Reference or source 
LTBP-1 
mouse monoclonal ab 
(MAB388) R&D Systems, Minneapolis, MN, USA 
LTBP-2, 
purified rabbit polyclonal ab (abL22) Hyytiäinen et al. 1998 
β1-LAP rabbit polyclonal ab (680) Taipale et al. 1995 
fibronectin rabbit polyclonal ab Sigma, St. Louis, MO, USA 
fibronectin mouse monoclonal ab (FN-15) Sigma 
collagen IV goat polyclonal ab Chemicon, Temecula, CA, USA 
laminin rabbit polyclonal ab Chemicon 
fibrillin-1 
mouse monoclonal ab 
(MAB11C1) Neomarkers, Fremont, CA, USA 
fibrillin-1 rabbit polyclonal ab pAb9543 
Dr. Lynn Sakai, Oregon Health and Science 
University, Portland, Oregon, USA 
Integrin α1 
subunit mouse monoclonal ab (FB12) Chemicon 
Integrin α2 
subunit mouse monoclonal ab (1IE6) Chemicon 
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Integrin α3 
subunit 
mouse monoclonal ab (ASC-
6) Chemicon 
Integrin α4 
subunit mouse monoclonal ab (P1H4) Chemicon 
Integrin α5 
subunit mouse monoclonal ab (P1D6) Chemicon 
Integrin α6 
subunit mouse monoclonal ab (GoH3)
BD Transduction laboratories, Lexington, Ky, 
USA 
Integrin αv 
subunit mouse monoclonal ab (M9) Chemicon 
Integrin αvβ3 
mouse monoclonal ab 
(LM609) Chemicon 
Integrin β1 
subunit  
mouse monoclonal ab (6S6 
and P5D2) Chemicon 
paxillin mouse monoclonal ab (177) BD Transduction laboratories 
vinculin 
mouse monoclonal ab (hVIN-
1) Sigma 
ERK1/2 rabbit polyclonal ab Promega, Madison, WI, USA 
P-p44/42 rabbit polyclonal ab Cell Signaling, Beverly, MA, USA 
P-Smad2 rabbit polyclonal ab (AB3849) Millipore, Temecula, CA, USA 
  
3.2 Production and purification of recombinant LTBP-2 and its 
fragments (I)   
Full length recombinant LTBP-2 was produced as described (Hyytiäinen et al. 1998). 
Briefly, conditioned medium from CHO-L2 clone was precipitated with 30% (w/v) 
(NH4)2SO4 at +4°C. The precipitate was dissolved in 50 mM Tris-HCl, pH 7.0, after 
which it was filtered and applied to MonoQ HR 5/5 column (Amersham Pharmacia 
Biotech, Uppsala, Sweden). The bound proteins were eluted with 210-700 mM NaCl 
gradient. LTBP-2 containing fractions were combined, and 4 M urea was added to achieve 
the final concentration of 2 M. The sample was applied to MonoQ 5/5 column equilibrated 
in 50 mM Tris-HCl, pH 7.0 containing 2 M urea. Proteins were eluted with 0-1 M NaCl 
gradient. The fractions containing LTBP-2 were fractionated on a Superdex 200 gel 
filtration column (Amersham Pharmacia Biotech) equilibrated with 50 mM Tris-HCl, pH 
7.5 containing 2 M urea. The buffer of LTBP-2 fractions was then changed to phosphate 
buffered saline (PBS, 0.14 M NaCl, 10 mM sodium phosphate buffer, pH 7.4) with Fast 
Desalting column HR 10/10 (Amersham Pharmacia Biotech). 
Expression and purification of LTBP-2 fragments as IgG Fc-tail fusion proteins was 
carried out essentially as described for LTBP-1 (Unsöld et al. 2001) and their structures  
are illustrated in Fig. 6. 
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Figure 6. Schematic representation of Ig-tagged LTBP-2 fragment used for cell adhesion 
studies. Adopted from I. 
3.3 Cell adhesion and transwell migration assays (I) 
Plates of 96 wells were coated with the indicated proteins diluted in PBS at +37°C for 2 h. 
The wells were incubated with 1% heat denaturated bovine serum albumin (BSA) in PBS 
at room temperature for 30 min to prevent non-specific binding of cells. The wells were 
washed with PBS before the addition of cells. Cells were detached with trypsin-EDTA and 
suspended at density of 6.0 x 105 cells/ml in serum-free minimum essential medium 
(MEM). Cell suspension (50 μl) was then transferred to each well. In inhibition studies the 
cells were incubated with antibodies or other agents of interest for 15 min before transfer 
to the wells. The antibodies were used at concentrations up to 25 μg/ml, the RGD peptide 
(GRGDTP, Sigma) at 100-500 μM and heparin (Leiras, Turku, Finland) up to 800 IU/ml. 
Each experimental condition was tested in triplicate. The cells were allowed to attach at 
+37°C for 1 h, after which nonattached cells were removed by washing with PBS. Cells 
were then fixed and stained simultaneously with 0.1 % Coomassie Blue in 10 % acetic 
acid and 40 % methanol, and washed with the same fixative without the dye. 
Subsequently, the cells were lysed in 100 μl of 1% SDS in PBS and the absorbance was 
measured at 620 nm. 
Transwell migration assays were performed using modified Boyden Chambers (Falcon 
cell culture inserts with 8 μm pores, Becton Dickinson, Franklin Lakes, NJ, USA). The 
upper and/or lower sides of the membranes of inserts were coated with the indicated 
concentrations of LTBP-2 or fibronectin (Sigma) at +37°C for 1 h, washed with PBS and 
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then treated with 1 % heat-inactivated BSA for 30. The inserts were then washed with 
PBS and placed in 24-well cell culture plates. Bowes melanoma cells were detached with 
trypsin-EDTA. The cells were suspended in MEM containing 0.1 % fetal calf serum 
(FCS) at the density of 1 x 106 cells/ml. Cell suspension (500 μl) was transferred to upper 
chambers and 750 μl of MEM with 0.1 % FCS was added to lower chambers. The cells 
were allowed to migrate in 5% CO2 at +37°C for 6 h. The cells were then fixed and stained 
with 40 % methanol, 10 % acetic acid and 0.1 % Coomassie blue for 5 min and washed 
with the same fixative without the dye. The cells that had not migrated through the pores 
were removed from the upper surface of the membrane with cotton swabs. The number of 
migrated cells was counted from three randomly chosen microscope fields of each 
membrane. All experiments were repeated at least three times. 
3.4 Protein analysis 
3.4.1 Immunofluorescence stainings (I, II, III, IV) 
The cells were allowed to attach to coated coverslips at +37°C for 2 h or grow on non-
coated coverslips for 2-14 or 4-6 d after which the cells were fixed with 3 % 
paraformaldehyde (PFA) for 15 min or with methanol at -20°C for 20 min. 
Permeabilization of cells was performed with 0.5 % NP-40 for 5 min. The cells were then 
treated with 5 % BSA for 30 min, washed with PBS, and incubated with primary 
antibodies for 1 h. Alternatively, living cells on glass coverslips were washed with ice 
cold PBS and incubated with primary antibodies on ice for 20 min prior to fixing and BSA 
treatment. Next the coverslips were washed with PBS followed by incubation with 
fluorescein conjugated secondary antibodies. The coverslips were washed and mounted on 
glass slides using Vectashield (Vector Laboratories, Burlingame, CA). The fluorescent 
images were obtained using Axioplan 2 imaging microscope (Zeiss). Images were 
acquired with AxioCamHRc camera (Zeiss) and AxioVision3.1 software (Zeiss).  
3.4.2 Isolation and plasmin digestion of ECM-associated proteins (II, III) 
The cells were cultured for the indicated times and sodium deoxycholate insoluble 
matrices were isolated and digested with plasmin to solubilize LTBPs (Taipale et al. 1994; 
Koli et al. 2005). Briefly, the cell cultures were washed once with PBS and extracted by 
0.5% sodium deoxycholate in 10 mM Tris–HCl buffer, pH 8.0, containing 150 mM NaCl 
and 1% NP-40, and clarified by centrifugation at 8000 × g for 10 min. The sodium 
deoxycholate insoluble material was then washed once with ice-cold PBS and digested 
with 0.3 U/ml of plasmin (Sigma) in PBS containing 1 mM MgCl2, 1 mM CaCl2 and 0.1% 
n-octyl-β-d-glucopyranoside (Sigma) at 37°C for 2 h. Protease inhibitors (Complete, 
Roche, Mannheim, Germany) were then added, and the supernatants clarified by 
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centrifugation. Subsequently, the soluble proteins were analyzed by SDS-PAGE and 
immunoblotting. 
3.4.3 SDS-PAGE and immunoblotting (II, III, IV) 
Proteins from the conditioned cell culture medium or ECM preparations were separated by 
SDS-PAGE under nonreducing conditions using 4-20% gradient Tris-HCl polyacrylamide 
gels (Cambrex). When necessary, conditioned cell culture medium was concentrated five-
fold using Microcon YM-30 centrifugal filter devices (Millipore, Bedford, MA, USA). 
Sample volume was corrected for protein concentration. Electrophoretically separated 
proteins were transferred to nitrocellulose membranes by semi-dry blotting, and 
subsequently treated with 5 % non-fat milk in PBS/Triton X-100 to saturate non-specific 
protein-binding sites. The membranes were then reacted with antibodies, washed and 
detected using HRP-conjugated secondary antibodies and enhanced chemiluminescence 
detection (ECL; Amersham). Incubations and washings were carried out in 50 mM Tris-
HCl buffer, pH 8.5, containing 0.5 M NaCl, 0.1 % BSA and 0.1 % Tween-20.  
3.4.4 Pulse-chase and immunoprecipitation (II) 
Human embryonic lung fibroblasts were cultured for 24 h or 4 days prior to labeling. First 
the cells were starved in methionine/cysteine –free MEM for 2 h followed by labeling with 
100 μCi/ml of [35S]-Cysteine (1000 Ci/mmol) in MEM containing 0.05 mM methionine at 
+37°C for 20 minutes. After the pulse the labeled proteins were chased in serum free 
MEM containing 0.05 mM methionine and 20x excess of cold L-cysteine at +37°C for 0-7 
h as indicated. At each time point the chase medium was collected, cells were lysed and 
their ECM was extracted. After the digestion plasmin activity was inhibited with protease 
inhibitor cocktail, (Complete, Roche).   Next the samples were incubated with non-
immune rabbit serum in an end-over-end rotary shaker at +4°C for 2 h followed by 
addition of protein A –sepharose (Protein A Sepharose 4B Fast Flow, Sigma) for 1 h. The 
beads were collected by centrifugation at 10 000 rpm for 10 minutes in a microcentrifuge. 
The samples were then transferred to fresh tubes and incubated with specific anti-serum 
against LTBP-2 (ab L22) at +4°C for 2 h followed by incubation with protein A Sepharose 
for 1 h. The immunocomplexes were harvested by centrifugation at 2000 rpm for 5 min. 
The beads were then washed twice with PBS, twice with detergent buffer (1% sodium 
deoxycholate, 1% TX-100, 150 mM NaCl in 50 mM Tris-HCl buffer, pH 7.0), once with 
high salt buffer (500 mM NaCl, 0.2% TX-100 in 20 mM Tris-HCl buffer, pH 7.0), 
followed by three washes with PBS. During the last wash the beads were transferred to 
fresh tubes. Bound proteins were eluted by heating at +95°C in SDS-PAGE sample buffer 
for 5 min and run in 7.5% Tris-Glycine precast gels as described above. The gels were 
fixed with 10% acetic acid/40% methanol for 20 min and incubated with enhancer 
solution (Amersham) for 30 min. Finally, the gels were dried and the signal was visualized 
by exposing on the film at -80°C for 1-14 days.  
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3.4.5 Analysis of ERK1/2 phosphorylation (III) 
Cells were treated with signal pathway inhibitors for 15 min prior to treatment with PMA. 
After 1 h the cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1 % 
NP-40, 0.5 % NaDOC, 0.1 % SDS) containing 1 mM NaVO4, 5 mM NaF and Complete 
protease inhibitor cocktail (Roche). Polypeptides from cell lysates were separated by SDS-
PAGE in non-reducing conditions, and phosphorylation of ERK1/2 was analyzed using 
specific antibodies against phospho-ERK1/2 and total ERK1/2. 
3.4.6 Gelatin zymography (III) 
Polypeptides of conditioned medium were separated under nonreducing conditions using 
10% polyacrylamide gels containing 1 mg/ml of gelatin. The gels were subsequently 
washed twice with solution containing 50 mM Tris-HCl pH 7.6, 5 mM CaCl2, 1 μM ZnCl2 
and 2.5% Triton X-100 for 15 min to remove SDS followed by a brief rinsing in washing 
buffer without Triton X-100. Next, the gels were incubated overnight at +37°C in a 
developing buffer containing 50 mM Tris-HCl pH 7.6, 5 mM CaCl2, 1 μM ZnCl2, 1% 
Triton X-100 and 0.02% NaNO3. The gels were then stained with Coomassie Blue for 2 h 
and destained with 10% methanol, 10% acetic acid.  
3.4.7 Immunohistochemistry and morphometric analysis (IV) 
Paraffin-embedded tissue samples of epithelial MM were deparaffinised in xylene and 
dehydrated in graded alcohol. Antigens were retrieved by heating the sections in citrate 
buffer (pH 6.0). The sections were stained using P-Smad2 and LTBP-1 antibodies and the 
Novolink staining system (Novocastra, Laboratories, Newcastle upon Tyne, UK). The 
specificity of the staining was assessed using PBS and rabbit isotype (Zymed, San 
Francisco, CA, USA) negative controls. Positive immunoreactivity was visualized using 
DAB (Novocastra), and nuclear counterstaining by haematoxylin.  
The percentage of P-Smad2 positive nuclei was calculated from each mesothelioma 
specimen manually using a standard hematological differential counter. Morphometric 
analysis of positive immunoreactivity for LTBP1-antibody was performed using Image-
Pro Plus 6.1 software (Media Cybernetics, Silver Spring, MD, USA). A representative 
image from each section´s tumor or stroma was taken with Olympus U-CMAD3 camera 
(Olympus Corporation, New York, NY, USA) and QuickPHOTO CAMERA 2.1 software 
(Promicra, Prague, Czech Republic). The areas of positive and negative staining were 
calculated.  
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3.4.8 TGF-β activity assay (IV) 
Mink lung epithelial cells stably transfected with a fragment of PAI-1 promoter fused to 
luciferase gene (TMLC) were provided by Dr. D.B. Rifkin (New York University School 
of Medicine, New York, USA). These cells produce luciferase in response to TGF-β and 
were used to assess the amount of active and total TGF-β in the cell conditioned medium. 
For measurement of total TGF-β activity the latent forms were activated by heating at 
+80°C for 5 min. The cells were incubated with TGF-β standards and aliquots of medium, 
and analyzed as described (Abe et al. 1994). The luciferase activity was normalized to cell 
number. 
3.5 RNA isolation, reverse transcription and real-time PCR (II, III, 
IV) 
Total cellular RNA was isolated using RNeasy Mini kit (Qiagen, Valencia, CA, USA). 
RNA concentrations and purities were determined spectrophotometrically (BioPhotometer 
6131, Eppendorf, Hamburg, Germany). Reverse transcription was carried out with 
Random hexamer primers (Invitrogen, Carlsbad, CA, USA) and Superscript III reverse 
transcriptase (Invitrogen) using 1.0 μg of total RNA according to manufacturer's 
instructions. The cDNAs were amplified using TaqMan Assays-on-Demand gene 
expression products (Applied Biosystems, Foster City, CA, USA) and GeneAmp 7500 
Sequence Detector thermal cycler (Applied Biosystems). The results have been expressed 
as mRNA expression levels normalized to the levels of a gene with a constant expression 
(GAPDH). 
3.6 Lentiviral silencing of mRNA expression (II, III) 
Plasmids expressing short-hairpin-RNAs targeted against fibrillin-1 or MT1-MMP were 
obtained from the RNAi Consortium via Open Biosystems. Four (III) or five (IV) different 
constructs for each gene were tested: TRCN0000050854 (designated as construct 1=Cstr1) 
TRCN0000050855 (=Cstr2) TRCN0000050856 (=Cstr3) TRCN0000050857 (=Cstr4) 
targeted MT1-MMP. TRCN0000055893 (designated as short hairpin 1=sh1), 
TRCN0000055894 (=sh2), TRCN0000055895 (=sh3), TRCN0000055896 (=sh4) and 
TRCN0000055897 (=sh5) targeted fibrillin-1. A scrambled construct was used as a 
control. 293FT producer cells were cotransfected with the packaging plasmid 
(pCMVdr8.74; see www.tronolab.epfl.ch), envelope plasmid (pMD2-VSVG; see 
www.tronolab.epfl.ch) and fibrillin-1-shRNA -plasmid (hairpin-pLKO.1 vector) or control 
plasmid (scrambled) by using the calcium phosphate precipitation method. Normal 
complete culture medium (MEM) was changed to the 293FT cells 24 h after transfection. 
The viral supernatants were harvested for 48 h, filtered through 0.45 μm filter and 
transferred to human lung fibroblasts. After 16 h infection the supernatants were replaced 
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with complete medium for the subsequent assays.  For stable shRNA expression the 
infected fibroblasts were subjected to selection with 5 μg/ml of puromycin for three days. 
The efficiency of the transduction was measured by monitoring the fibrillin-1 expression 
by quantitative real-time-PCR.  
3.7 Patients and tissue specimens (IV)  
Pleural tissue was obtained from surgical pleurectomy from patients with MM or non-
malignant lung tumors (hamartomas) or from diagnostic procedures of granulomatous 
diseases at the Helsinki University Central Hospital. The study has been accepted by an 
ethical board and registered (www.hus.fi/clinicaltrials). The MM tumor array was 
constructed as described and the mean survival of patients after the diagnostic biopsy was 
taken was 18.7 months (Lindholm et al. 2009). 
3.8 siRNA transfections (IV)   
Human mesothelioma cells or Met5A control cells were transfected with siRNAs targeted 
against LTBP-1 and LTBP-3 or a negative control (Qiagen). The cells were allowed to 
attach for 4 hours before an overnight transfection, which was performed using 
Lipofectamine 2000 reagent (Invitrogen). Fresh culture medium was then changed and the 
cells were cultured for the indicated times before subsequent analyses. The total RNAs 
were isolated at 5 d. The mRNA expression levels were analyzed by quantitative RT-PCR.   
3.9 Statistical analysis (IV)   
PASW software was used for statistical analysis. For comparison of mean in the tumor 
tissue and stroma, nonparametric Mann-Whitney test was used, and the data was presented 
as boxplots. For analysis of correlation between different variables, Spearman´s linear 
regression analysis was used. For evaluation of mortality, a Kaplan-Mayer survival curve 
was generated.  
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4 Results 
4.1 LTBP-2 is an adhesion protein for melanoma cells (I) 
4.1.1 Melanoma cells attach to LTBP-2  
To explore the effects of LTBP-2 on cell adhesion we produced recombinant LTBP-2 and 
partially overlapping fragments that covered the whole protein. We tested several cell 
lines of different origin, such as human lung fibroblasts, endothelial cells, fibrosarcoma 
and osteosarcoma cells, to analyze their abilities to bind to purified LTBP-2. We found 
that all the melanoma cell lines tested adhered to LTBP-2 (Fig. 1A). Further 
characterization of Bowes cells revealed that the cells adhered to LTBP-2 in a 
concentration dependent manner (Fig. 1B). The adhesion was associated with cell 
spreading and formation of extensive filopodia (Fig. 1C). 
To test the specificity of the Bowes cells adhesion to LTBP-2 we treated the LTBP-2 
coated wells with polyclonal antibody, abL22, generated against recombinant LTBP-2, 
before the adhesion assay. The treatment only partially (by 40 %) inhibited the cell 
adhesion (Fig. 5C), which might be explained by the observation that abL22 does not 
recognize the N-terminal epitopes of LTBP-2 as well as C-terminal ones (Hyytiäinen M. et 
al., unpublished data). Incubation of Bowes cells with soluble LTBP-2 (5 μg/ml) before 
plating decreased cell adhesion by ~15 % (Fig. 5C) suggesting that cells cannot efficiently 
bind soluble LTBP-2.  
4.1.2 Bowes cell adhesion to LTBP-2 is β1 –integrin dependent and 
associated with the formation of focal adhesions 
The RGD sequence, commonly recognized by integrin receptors, is located to the N-
terminus of LTBP-2. This raised the hypothesis that the interaction of Bowes melanoma 
cells with LTBP-2 could be mediated by one or more receptors of integrin type. We 
utilized a number of monoclonal anti-integrin antibodies in order to inhibit cell adhesion. 
Bowes cell adhesion to LTBP-2 was completely blocked by the anti-β1 integrin antibody 
(Fig. 2A). In addition, the antibody against the integrin α3 subunit decreased cell adhesion 
by 50 %, while mABs recognizing the α subunits 1, 2, 4, 5, and V did not have any effect. 
mAB against the integrin α6 subunit had a small decreasing effect on the adhesion and 
enhanced the inhibitory effect of the anti-α3 antibody. α3β1 and α6β1 are known as 
laminin receptors (van der Flier and Sonnenberg 2001). When used in combination, but 
not individually, the anti-α3 and anti-α6 antibodies decreased Bowes cell adhesion to 
LTBP-2 as efficiently as Bowes cell adhesion to laminin (Fig. 2B).  
The localization of β1 and α3 integrins in melanoma cells adhered to LTBP-2 was 
analyzed by immunofluorescence. The fluorescence signal for the both of them was 
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localized mostly to the cell membrane or just beneath it, especially in the lamellipodia, in 
plaque like structures (Fig. 3). In addition, paxillin and vinculin, which are involved in 
connecting the integrins to the actin cytoskeleton (Zamir and Geiger 2001), were localized 
to the cell periphery in similar structures further confirming the formation of focal 
contacts after ligand recognition.  
4.1.3 Melanoma cell attachment to LTBP-2 is mediated by N-terminal 
fragment that does not contain the RGD sequence 
Since the α3β1 integrin recognizes the RGD sequence in some ligands (Plow et al. 2000; 
Akula et al. 2002), we tested whether an RGD peptide could interfere with Bowes 
melanoma cell adhesion to LTBP-2. RGD peptide [500 μM] decreased Bowes cell 
adhesion to LTBP-2 by 40% while it totally prevented cell adhesion to FN and vitronectin 
(Fig. 5A).  
Considering that cell surface PGs are important modulators of cell adhesion and 
HSPGs can co-operate with integrins (Bernfield et al. 1999) we examined whether Bowes 
cell adhesion to LTBP-2 would be affected by heparin, a wide range inhibitor of cell 
adhesion. Pre-treatment with heparin inhibited Bowes cell adhesion to LTBP-2 in a 
concentration dependent manner (Fig. 5B).  
To identify the adhesive sites in the LTBP-2 protein we produced recombinant 
fragments covering the whole protein (Fig. 6B). Bowes cells did not adhere to any of the 
fragments as efficiently as to the full length LTBP-2 (Fig. 6A). The fragments most 
potently mediating the cell attachment were located to the N-terminus. These fragments 
contain a common proline–rich region. The cells could not attach to the short RGD 
containing fragment, but adhered to adjacent, proline rich fragment indicating that Bowes 
cell adhesion to LTBP-2 is not dependent on the RGD sequence.  
4.1.4 LTBP-2 supports migration of Bowes melanoma cells 
We explored whether melanoma cell could migrate towards LTBP-2 in addition to 
adhering to it. We used purified LTBP-2 for coating and FN, which is haptotactic for a 
variety of cell lines (Postlethwaite et al. 1987), served as a control. Bowes cells migrated 
very poorly when LTBP-2 was coated only on the upper surface of the membrane of cell 
culture insert (Fig. 7). When LTBP-2 was coated on the lower surface, the cells migrated 
towards it. Coating of both sides with LTBP-2 further increased cell migration, the pattern 
being very similar to Bowes cell migration on FN. These data suggest that LTBP-2 can 
support haptotactic migration of melanoma cells.  
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4.2 Characterization of matrix association of LTBP-2 (II) 
4.2.1 LTBP-2 colocalizes temporally with fibronectin in human lung 
fibroblast cultures  
 
LTBP-2 is highly expressed in the lung (Shipley et al. 2000) and thus we chose to use 
human embryonic lung fibroblasts as a model for analyzing matrix association of LTBP-2. 
We followed the formation of the ECM by immunofluorescence analysis. FN formed 
extensive networks already on day 2, whereas LTBP-2 was detected mostly inside the 
cells (Fig. 1A). Fibrillar LTBP-2 structures were visible on day 4 and they colocalized 
with FN. Later, LTBP-2 became organized into a fibrillar network and the maximum co-
distribution with FN was observed at days 7-10. After that their co-localization started to 
diverge.  
The expression of LTBP-2 mRNA increased about 2-fold during the first 7 days and 
reached the highest level, ~2.5 fold increase, at two weeks of culture (Fig. 1B). Analysis 
of the protein levels of secreted LTBP-2 revealed that LTBP-2 was secreted into the 
culture medium at relatively high levels peaking on day 4 (Fig. 1C).  The peak in the 
secretion of LTBP-2 coincided with the time of the appearance of LTBP-2 network.  
4.2.2 LTBP-2 is rapidly secreted and deposited to the ECM in 5 d fibroblast 
cultures 
According to the protein levels, LTBP-2 was secreted into the cell culture medium already 
at the early time points, but it was not assembled into the matrix as assessed by 
immunofluorescence analysis. To explore the kinetics of LTBP-2 secretion and matrix 
deposition, we metabolically labeled the proteins of 1- and 5-day-old fibroblast cultures, 
the former being a subconfluent culture and the latter fully confluent. The labeled proteins 
were chased for the indicated periods of time and subjected to immunoprecipitation. We 
found that LTBP-2 was secreted from the cells within 3 h in 1-day-old cultures and within 
1 h in 5-day-old cultures (Fig. 2). The level of secreted LTBP-2 increased up to the 7 h 
time point in both cultures. LTBP-2 was barely detectable in the plasmin extracted 
matrices of subconfluent 1-day-old cultures. In contrast, LTBP-2 was deposited to the 
ECM in fully confluent 5-day-old cultures already within 30 min.  
4.2.3 LTBP-2 fails to assemble to the extracellular matrix of FN -/- fibroblast  
Earlier work from our laboratory revealed an interaction of LTBP-2 with FN (Hyytiäinen 
and Keski-Oja 2003). Further, FN was found to be indispensable for the matrix assembly 
of both LTBP-1 and LTBP-4 (Dallas et al. 2005; Kantola et al. 2008). To explore whether 
FN was essential also for the matrix deposition of LTBP-2, we analyzed the levels of 
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LTBP-2 in the FN deficient mouse embryonic fibroblasts by immunoblotting of cell 
conditioned medium and by immunofluorescence. Both the wild type (+/+) and FN null (-
/-) cells secreted LTBP-2 into the medium but the amount of LTBP-2 was clearly lower in 
the medium of FN -/- cells (Fig. 3A). When exogenous LTBP-2 was added to the medium 
of cells for the last 3 days of culture larger amounts of soluble LTBP-2 remained in the 
medium of -/- than +/+ cells as assessed by immunoblotting. Accordingly, 
immunofluorescence analysis indicated that LTBP-2 fibers were assembled to the ECM of 
FN +/+ mouse fibroblasts whereas there were no detectable LTBP-2 fibers in the ECM of 
FN -/- cells (Fig. 3A). The deposition of fibrillar LTBP-2 was fully rescued by cellular FN 
and to lesser extent by plasma FN (Fig. 3B). Fibrillin-1 deposition, which appears to be 
dependent on FN assembly (Kinsey et al. 2008), was accordingly rescued under the same 
conditions.   
4.2.4 LTBP-2 colocalizes with fibrillin-1 
LTBP-2 binds to fibrillin-1 but not to fibrillin-2 (Hirani et al. 2007). LTBP-2 and fibrillin-
1 also colocalize in human aorta. To analyze whether they might also colocalize in 
cultured human lung fibroblasts we cultured fibroblasts for 2-14 days, and visualized 
fibrillin-1 and LTBP-2 in the ECM by immunofluorescence. Both formed visible networks 
by 4 days the fibrillin-1 fibers being more abundant than LTBP-2 fibers suggesting that 
fibrillin-1 assembly precedes the deposition of LTBP-2 (Fig. 4). From then on the two 
proteins partially colocalized.  
We examined next whether LTBP-2 colocalizes with fibrillin-1 in other types of 
cultured cells. LTBP-2 fibers were assembled to the ECM of MG-63 osteosarcoma cells 
and human endothelial cells (HUVECs), which both exhibited also fibrillin-1 network in 
their ECM (Fig. 5C). The two proteins also partially colocalized. 
4.2.5 Matrix association of LTBP-2 depends on fibrillin-1 
Given that LTBP-2 was detected in the ECM considerably later than FN but soon after the 
appearance of fibrillin-1 we investigated whether the assembly of LTBP-2 into the ECM 
depends on fibrillin-1. We used lentiviral shRNAs to suppress the expression of fibrillin-1 
and achieved ~ 95% reduction of fibrillin-1 mRNA level with the most efficient shRNA 
construct (shRNA4; Fig. 6A). The assembly of matrix proteins into the ECM was 
monitored by growing the cells on coverslips for 7 days followed by fixation and 
immunofluorescence analysis. Extensive networks of both LTBP-2 and fibrillin-1 were 
detected in the ECM of control cells (Fig. 6C). As expected, there were no detectable 
fibrillin-1 fibers in shRNA4 expressing cells. Interestingly, the LTBP-2 network was also 
ablated in fibrillin-1 deficient cells. In contrast, the assembly of FN or LTBP-1 was not 
affected by the suppression of fibrillin-1 expression.  
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4.3 LTBP-1 is released from endothelial ECM via MT1-MMP (III) 
4.3.1 Release of ECM-bound LTBP-1 and LL-TGF-β in association with 
morphological change of endothelial cells 
Activation of quiescent endothelial cells by inflammatory cytokines is associated with a 
morphological change of the cells from cobble-shaped into migratory spindle-shaped 
phenotype (Romero et al. 1997; Karasek 2007). This morphological activation can be 
induced by IL-1β, INF-γ, TNF-α and PMA (phorbol 12-myristate 13-acetate) (Montesano 
et al. 1985; Bujan et al. 1999). As expected, in response to PMA, HUVECs changed their 
appearance from epitheloid into elongated fibroblast-like morphology (Fig. 1A). The fate 
of LTBP-1 during morphological activation of HUVECs was determined by 
immunofluorescence analysis. LTBP-1 formed a dense fibrillar network in the ECM of 
confluent endothelial cells (Fig. 1A). Notably, LTBP-1 network was almost completely 
depleted from the ECM during 48 h PMA-treatment (Fig. 1B). LTBP1 depletion coincided 
with efficient degradation of another main component of subendothelial matrix, collagen 
type IV. In addition, the staining patterns of laminin, LTBP-2 and FN showed fragmented 
appearance.  
Results of quantitative RT-PCR analysis indicated that HUVECs express mainly TGF-
β1 out of the three known TGF-β isoforms and LTBP-1 was the main isoform of the TGF-
β binding LTBPs (Fig. 2A). To detect LTBP-1 and TGF-β complexes in the crosslinked 
ECM, the matrices were isolated and digested with plasmin. The majority of the ECM-
bound LTBP-1 was detected in free form as indicated by the abundance of 125-
140 fragments in immunoblots, and 240 kDa bands representing LL-TGF-β were also 
detected (Fig. 2B). No other LTBP complexes were detectable with β1-LAP antibodies 
indicating that TGF-β1 forms complexes mainly with LTBP-1 in these cells. Markedly, 
the ECM of PMA-treated cells was depleted of both free LTBP-1 and LL-TGF-β1 in a 
time-dependent manner. 
To determine whether the release of LTBP-1 from ECM involved proteolytic 
processing of LTBP-1 and LL-TGF-β1 we analyzed the cell conditioned media of 
HUVECs by immunoblotting. After treatment of the cells with increasing concentrations 
of PMA, LTBP-1 appeared in the conditioned medium as truncated fragments indicating 
proteolytical cleavage (Fig. 2C). Similarly, LL-TGF-β of a 260-280 kDa was processed to 
a truncated ~240 kDa form. A minor band of ~100 kDa, corresponding to the size of small 
latent TGF-β1 complex, was also detected. In contrast, the migration pattern of highly 
homologous non-TGF-β binding LTBP-2 was not notably altered by PMA indicating that 
the processing was specific for LTBP-1. 
PMA is a direct protein kinase C (PKC) agonist which can activate ERK1/2 and PI-3 
kinase pathways (Ilan et al. 1998; Taylor et al. 2006). Accordingly, PKC and ERK1/2 
activities were needed for PMA induced processing of LTBP-1 (Fig. 3). 
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4.3.2 The processing of LTBP-1 and the release of matrix-bound TGF-β are 
mediated by MT1-MMP 
To dissect the LTBP-1 and TGF-β releasing proteases, we examined the effects of a panel 
of protease inhibitors on the ECM localization of LTBP-1 by immunofluorescence 
analysis. The synthetic wide spectrum inhibitor against the metalloproteolytic activities of 
MMPs and a-disintegrin-and-metalloproteinases (ADAMs) TAPI-1 and another synthetic 
metalloproteinase inhibitor GM6001 markedly decreased the release of LTBP-1 
suggesting the involvement of metalloproteinases in the process (Fig. 4). In contrast, the 
serine protease inhibitors had only negligible effects.  
Given the suggested roles of MMP-2 and MMP-9 in the release of LL-TGF-β and 
TGF-β activation (Dallas et al. 2002; Yu and Stamenkovic 2000) we analyzed their 
activities of in HUVECs by gelatin zymography assay. Consistent with previous reports 
(Lohi et al. 1996), the expression of MMP-9 was markedly upregulated by PMA (Fig. 
5A). MMP-2 was expressed at a constant level and activated in response to PMA.  Since 
MMP-2 activation can be induced by both MT-MMPs and plasmin (Monea et al. 2002), 
we analyzed the effects of metalloprotease and serine protease inhibitors in this assay. 
Only the metalloproteinase inhibitors efficiently prevented the activation of MMP-2.  
Determination of mRNA levels by quantitative RT-PCR revealed that MT1-MMP was 
the only notably expressed MT-MMP in HUVECs (Fig. 5B). In addition, ADAMs -10 and 
-17 were also expressed although on much lower level. Importantly, MT1-MMP 
expression was markedly induced by PMA treatment whereas the expression levels of 
MT2-MMP and MT3-MMP as well as ADAMS -10 and -17 remained essentially 
unaltered (Fig. 5C). 
 Considering the specific up-regulation of MT1-MMP expression and MMP-2 
activation we examined the effects of tissue inhibitors of metalloproteinase (TIMPs) 1-3, 
which display different specificities for metalloproteinases. We found that TIMP-3, the 
inhibitor of all MMPs and several ADAMs, efficiently prevented the proteolytic 
processing of LTBP-1 and LL-TGF-β1 (Fig 6). In contrast, TIMP-1, which inhibits 
secreted MMPs and ADAM-10, did not have any effect. TIMP-2 inhibits both soluble 
MMPs and MT-MMPs and it partially prevented the proteolysis of LTBP-1 and LL-TGF-
β1. The suggested involvement of MT1-MMP in the process was finally tested by 
lentiviral shRNA mediated suppression of its expression. Indeed, the 90% knock-down of 
MT1-MMP mRNA levels prevented the processing and release of LTBP-1 indicating that 
the PMA induced release of LTBP-1 and LL-TGF-β1 from endothelial ECM is mediated 
by MT1-MMP (Fig. 7). 
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4.4 Roles of LTBPs -1 and -3 in mesothelioma (IV) 
4.4.1 Mesothelioma cells show high P-Smad2 immunoreactivity compared to 
stromal cells 
The important role of TGF-β has been implicated in the pathogenesis of malignant 
mesothelioma (MM) (Fitzpatrick et al. 1995; Bielefeldt-Ohmann et al. 1996). To assess 
the TGF-β activity in tumor biopsies we used phosphorylated Smad2 (P-Smad2) as an 
indicator of active TGF-β signaling. Total of 28 human MM biopsies were tested for P-
Smad2 immunoreactivity. Positive staining was observed in the nuclei both in tumor tissue 
and stroma (Fig. 1A). The percentage of positive nuclei was calculated from each biopsy. 
Approximately 70% of the tumor cell nuclei were positive for P-Smad2, whereas the mean 
percentage in the stroma was only ~24% (Fig. 1B). Next Kaplan-Meier plots were 
generated from high and low tumor P-Smad2 ratios to assess whether P-Smad2 levels in 
the tumor tissue would be related to patient survival. A clear trend towards better survival 
was observed in the samples with low P-Smad2 levels (Fig. 1C). 
 
4.4.2 Expression levels of TGF-β and LTBP isoforms in tissue biopsies 
The relative expression levels of TGF-β isoforms in mesothelioma tissue biopsies and 
healthy pleura were determined by quantitative RT-PCR. TGF-β1 was the most prominent 
isoform in both normal and tumor tissue and upregulated in all four MM samples (Fig. 
2A). In addition, upregulation of TGF-β2 in MM was observed. 
 The analysis of mRNA expression levels of LTBP isoforms showed that all LTBPs 
were expressed in normal pleura but LTBP-3 was clearly the main isoform (Fig. 2B). The 
expression levels in MM biopsies varied markedly but the ratio of LTBP-1 to LTBP-3 
mRNA level was clearly increased in 3/4 tumor samples compared to the ratio in normal 
pleura (Table 1).  
4.4.3 LTBP-1 immunoreactivity is high in the tumor stroma 
To analyze the localization of LTBP-1 protein in tissue samples we performed 
immunohistochemical analysis of 19 MM biopsies. Due to the lack of suitable antibodies 
we were unable to assess the localization of LTBP-3 or LTBP-4. We detected some 
LTBP-1 immunoreactivity in the tumor tissue but especially the tumor stroma was 
intensively stained (Fig. 2C). Quantification of LTBP-1 positive area in tumor vs. stroma 
by morphometric analysis indicated that ~28% of the stroma was LTBP-1 positive 
whereas less than 5% of the tumor area stained for LTBP-1. The correlation between 
LTBP-1 and P-Smad2 immunoreactivity was negative when both tumor and stroma was 
analysed (P=0.009, R=-0,55, Spearmans test).   
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4.4.4 TGF-β activity is increased in cultured mesothelioma cells 
To gain insight into LTBP mediated TGF-β activation, non-tumorigenic Met5A cells and 
two mesothelioma cell lines (M14K and M38K) were selected for in vitro studies.  
Secreted TGF-β activity was measured from conditioned cell culture medium using the 
TMLC reporter cells. Elevated secretion of both active and total TGF-β was found in the 
medium of cultured MM cells (Fig. 3), consistent with the increased TGF-β signaling 
observed in tumor biopsies. Moreover, mRNA expression profiles of TGF-β and LTBP 
isoforms were similar to those of the tumor samples as illustrated by mRNA expression 
levels (Fig. 4) and increased LTBP-1 to LTBP-3 ratio in MM cells (Table 2).  
4.4.5 Reduced LTBP-3 mediated targeting of TGF-β increases TGF-β activity 
but reduces proliferation of mesothelioma cells 
To dissect the specific roles of LTBP-1 and LTBP-3 in the secretion and activation of 
TGF-β by MM cells we analyzed the activity of TGF-β after siRNA mediated suppression 
of LTBPs. Reduction of LTBP-3 but not of LTBP-1 mRNA levels resulted in increased 
secretion of active TGF-β by MM cells (Fig. 5A). This was not observed in Met5A cells. 
However, since the basal LTBP-3 mRNA expression is very high in Met5A cells, the 
efficiency of the siRNAs may not have been sufficient for altering the TGF-β activation. 
To determine the effect of the suppression of LTBP-3 expression on cell proliferation the 
cells were maintained in complete culture medium for 5 days after siRNA transfection 
followed by counting the cell numbers. In LTBP-3 siRNA transfected MM cells the 
increased TGF-β activity was associated with over 40% of reduction in cell number (Fig. 
5B).  The effect of LTBP-1 suppression on MM proliferation was only modest and the 
proliferation of Met5A cells was not affected.  
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5 Discussion 
5.1 Adhesive functions of LTBP-2 
LTBP-2 deficiency in the mouse leads to early embryonic lethality coinciding with the 
time of implantation (Shipley et al. 2000). The possible defect in implantation could 
suggest a role for LTBP-2 in cell adhesion. We tested several cell types, both primary and 
immortalized as well as cancer cells, for their ability to adhere to purified recombinant 
LTBP-2 coated on a cell culture plate. Unexpectedly, only melanoma cells adhered to 
LTBP-2. Most notably, this was applied to seven different melanoma cell lines although 
there was variation in the magnitude of adhesion. Further characterization of Bowes cells 
showed that the adhesion was mediated by β1 integrin receptors, most likely via α3β1 and 
α6β1. The differences in the efficacy of anti-integrin antibodies could reflect the amount of 
the receptor on the surface of melanoma cells or the properties of the antibodies. Both 
types of integrin receptors are expressed in melanoma cells (Zhu et al. 2002; Tsuji et al. 
2002). However, the presence or absence of these receptors on different cell types does not 
alone explain their ability to adhere to LTBP-2. For example, HT-1080 fibrosarcoma cells 
and lung fibroblasts express integrins α3β1 and α6β1 but do not adhere to LTBP-2, which 
implies that additional mechanisms are involved. Various cell surface proteins or PGs, 
such as uPAR, thrombospondin or tetraspanins, modulate integrin functions (Ossowski 
and Aguirre-Ghiso 2000; Roberts 1996b). Therefore, we examined the effects of heparin 
in adhesion assays. Melanoma cell adhesion could be inhibited by heparin suggesting that 
HSPGs might be involved. However, when we explored the effect of heparan sulfate we 
could not observe any effect on Bowes cell adhesion to LTBP-2 (data not shown). This 
might implicate the involvement of very specialized form of cell surface HSPG. 
We were not able to inhibit the melanoma cell adhesion to LTBP-2 with a synthetic 
RGD peptide even at concentration which was enough to totally prevent cell adhesion to 
FN and vitronectin suggestive of RGD independent mechanism. Cell adhesion to a related 
protein, fibrillin-1, displays cell type specific differences (Sakamoto et al. 1996). Various 
cell lines adhere to fibrillin-1 via RGD dependent recognition by αvβ3 integrin, and 
dermal fibroblasts bind also via α5β1 (Bax et al. 2003). Chondrocytes, instead, utilize 
some other, non-RGD containing domain (Sakamoto et al. 1996). Moreover, α3β1 and 
αvβ3 are involved in fibroblast adhesion to fibrillin-2 in RGD dependent manner. 
However, in fibrillins, the RGD sequence recognized by integrins is located to the fourth 
8-Cys repeat where it is suggested to be part of a loop-like structure available for cellular 
interactions (Yuan et al. 1997; Bax et al. 2003). The RGD in LTBP-2 resides in between a 
domain of four cysteine repeats and an EGF-like repeat in the N-terminus of the protein. It 
is not a hydrophobic region but differs from the structure of the 8-Cys repeat and most 
likely is not as well exposed. The N-terminus of LTBP-1 and LTBP-2 mediate the ECM 
association (Nunes et al. 1997; Unsöld et al. 2001; Hyytiäinen and Keski-Oja 2003), 
which presumably affects the conformation of the protein. 
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We attempted to locate the adhesive site in LTBP-2 by using fragments of different 
lengths that covered the whole protein. However, none of the fragments was as strong 
adhesive substrate as the full length protein. The most potent was a proline-rich region in 
the N-terminus of LTBP-2 but not the adjacent fragment that contains the RGD sequence. 
The inefficacy of the fragments to support cell adhesion could be explained with 
differences in conformation compared to the full length protein, especially considering the 
dimeric nature of the Ig fusion proteins. However, we observed melanoma cell adhesion to 
the same domain produced with histidine tag but again, it was only modest compared to 
the adhesion to the full length LTBP-2 (Vehviläinen et al., unpublished results). This 
leaves us with a possibility that the integrin binding epitope is discontinuous in LTBP-2.  
Interestingly, the same proline-rich N-terminal domain associates with ECM and mediates 
anti-adhesive functions on fibroblasts adhered FN (Hyytiäinen and Keski-Oja 2003). The 
mechanism involves binding of LTBP or its fragment to FN and results in disruption of 
actin cytoskeleton of the fibroblasts. Melanoma cells and fibroblasts might recognize the 
corresponding fragment by different mechanisms.  
Soluble LTBP-2 was not able to compete with the LTBP-2 coated on cell culture plate 
in adhesion assays suggesting that the adhesive properties of LTBP-2 are dependent on its 
deposition to substratum. It is very likely that the conformation of the protein is different 
in solution and potential adhesion sites are not accessible to cell surface receptors. 
Immobilizing the substrate to plastic or glass might resemble the in vivo situation. 
In addition to adhesion, LTBP-2 supported Bowes melanoma cell migration. Dynamic 
disruption and establishment of cell-substrate contacts is important for cell migration and 
cancer invasion. Although cell adhesion to LTBP-2 is not a common phenomenon, the 
melanoma cell adherence and migration on LTBP-2 may reflect the ability of cancer cells 
to acquire new properties that can be beneficial during invasion and metastasizing.  The 
melanoma cell lines used in this work were of diverse origin and their invading capacities 
vary. Hence, conclusions about the association of the grade of malignancy with the 
strength of adhesion could not be drawn. Melanoma cells are derived from melanocyte 
precursors and the ability of melanocytes to adhere to LTBP-2 is yet to be defined. 
In the beginning of these studies there were no known molecules interacting with 
LTBP-2. However, during the course of this work binding of LTBP-2 to fibrillin-1 and 
fibulin-5 was characterized (Hirani et al. 2007; Hirai et al. 2007) but interactions with cell 
surface molecules have not been reported. 
5.2 Association of LTBP-2 with the ECM 
LTBP-2 is a microfibril-associated molecule which is highly expressed in the lung and 
arteries, and was recently linked to the regulation of elastic fiber assembly (Hirai et al. 
2007). We wanted to examine the kinetics and determinants of matrix deposition of 
LTBP-2 using human lung fibroblasts as a model. 
We detected LTBP-2 in the ECM of lung fibroblasts after 4 days of subculture and it 
partially colocalized with FN during the following days. After extended (14 d) culture 
these proteins started to diverge into separate fibrillar networks. This is consistent with the 
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observations made for the other three LTBPs (Dallas et al. 2005; Koli et al. 2005). 
However, clear differences were found in the timing of the LTBP-2 matrix deposition 
compared to the assembly of TGF-β binding LTBPs: LTBP-2 appeared in the ECM later 
than LTBP-1 but earlier than LTBP-3 resembling the timing of LTBP-4 assembly (Koli et 
al. 2005). Furthermore, there was only modest increase in the mRNA levels of LTBP-2 
during 14 days of culture whereas the expression levels of LTBP-3 and -4 were induced 
by 7- and 4-fold suggesting that the regulation of the mRNA levels could be more 
important for matrix deposition of LTBP-3 and -4 than for LTBP-2. In fact, LTBP-2 was 
detected intracellularly and also in the conditioned medium already at early days of culture 
indicating that the delayed deposition of LTBP-2 due to the absence of an appropriate 
scaffold. Accordingly, the level of soluble LTBP-2 peaked at day 4, after which the 
accumulation of LTBP-2 into the ECM was detectable by both immunofluorescence and 
pulse-chase analysis.  Consistent with studies on LTBP-1 secretion (Taipale et al. 1994; 
Dallas et al. 2002) LTBP-2 was rapidly secreted from cells. In confluent, 5-day-old 
cultures, the secretion was coupled with subsequent association of LTBP-2 to the ECM 
resembling the kinetics of secretion and matrix association of LTBP-1 in osteoblasts 
(Dallas et al. 2002). In contrast, LTBP-2 failed to efficiently assemble to the ECM of 
subconfluent 1-day-old cultures suggestive of requirement for an appropriate scaffold, 
such as FN, and implicative of incapability of LTBP-2 for self-assembly. Interestingly, 
LTBP-1 is detected in the ECM of fibrosarcoma cells after 2 h (Taipale et al. 1994), which 
is considerably later than in osteoblasts and might reflect the differences in the 
accumulation of ECM proteins needed for LTBP-1 assembly.  
FN is widely distributed in fibrillar ECM structures, especially in provisional matrices 
during wound healing (Mosher 1995). It also regulates the assembly of various matrix 
proteins such as collagen I, thrombospondin, fibrinogen, LTBP-4 and fibrillin-1. As 
expected, we did not detect LTBP-2 in the ECM of FN deficient mouse embryonic 
fibroblasts even though exogenous LTBP-2 was added on the cells. The abundance of FN 
network in 1-day-old cultures of human fibroblasts and the much later deposition of 
LTBP-2 fibrils suggest that FN alone may not be sufficient for efficient assembly of 
LTBP-2. 
 LTBP-2 interacts with fibrillin-1 and these proteins co-localize in human embryonic 
aorta (Hirani et al. 2007). We found that the association of LTBP-2 with the ECM always 
coincided with the fibrillin-1 distribution in various cultured cell lines. In fibroblast 
cultures the appearance of fibrillar fibrillin-1 structures preceded the assembly of LTBP-2 
network. Fibrillin-1 assembly followed similar timing in dermal fibroblasts (Kinsey et al. 
2008). Thus, we hypothesized that fibrillin-1 network could promote the incorporation of 
LTBP-2 into the ECM. Indeed, we found that suppression of fibrillin-1 expression resulted 
in profound ablation of fibrillar LTBP-2 in the fibroblast ECM indicating that fibrillin-1 
was necessary for efficient assembly of LTBP-2. Matrix association of fibrillin-1 depends 
on cellular FN and could be rescued only in part by plasma FN (Kinsey et al. 2008). 
Consistent with these data, we observed stronger rescue of LTBP-2 deposition to the ECM 
of FN -/- mouse embryonic fibroblasts by cellular than by plasma FN.  
In contrast to LTBP-2, LTBP-1 is not dependent on fibrillin-1 for its matrix deposition 
(Dallas et al. 2005) although it binds to the same site in fibrillin-1 as LTBP-2 (Hirani et al. 
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2007). Our results further confirmed that fibrillin-1 knock-down does not affect the ECM 
association of LTBP-1. LTBP-2 thus clearly differs from LTBP-1 in the respect that its 
matrix assembly requires fibrillin-1. The differences in the requirements for matrix 
assembly may affect the tissue distribution of different LTBPs and the composition of 
microfibrils. A recent report described that the deposition of LTBP-1 and -4 depends also 
on fibrillin-1 (Ono et al. 2009). However, the fibroblasts used in that study were derived 
from neonatal skin of fbn1 null mice and did not deposit fibrillin-2 fibrils.  Thus, they 
could not rule out the possible involvement of fibrillin-2 in the incorporation of LTBP-1 
into the ECM. The lung embryonic fibroblasts used in our experiments express also 
fibrillin-2 (Charbonneau et al. 2003). Furthermore, LTBP-1 binds to fibrillin-2 whereas 
LTBP-2 does not (Isogai et al. 2003; Hirani et al. 2007). Therefore, it is likely that 
fibrillin-2 mediates the deposition of LTBP-1 in the absence of fibrillin-1, but it cannot 
compensate for the loss of fibrillin-1 in the process of LTBP-2 assembly.  
Deposition of fibulin-5/DANCE is dependent on fibrillin-1 in human skin fibroblasts, 
and LTBP-2 promotes fibulin-5 deposition on fibrillin-1 but not on fibrillin-2 and thus 
directs elastogenesis preferably onto fibrillin-1 microfibrils (Hirai et al. 2007). In addition, 
LTBP-2 knock-down rescues the fibrillin-1 independent elastin deposition. These data 
together with our results indicate that LTBP-2 directed inhibition of elastin deposition in 
the absence of fibrillin-1 results from the failure of LTBP-2 to associate with the ECM. 
However, the effects of LTBP-2 on elastogenesis cannot explain the early lethality of 
LTBP-2 -/- mice as they die already before elastin or fibrillin-1 expression is detected. 
5.3 MT1-MMP mediated release of LTBP-1 and LL-TGF-β1 in 
endothelial cells 
TGF-β plays an important role in maintaining the vascular homeostasis as well as in the 
regulation of angiogenesis. Since the release of ECM-bound latent TGF-β is considered as 
one of the regulatory steps in TGF-β activation we wanted to explore the fate of LTBP-1 
during endothelial cell activation. We found that the morphological activation of 
endothelial cells was accompanied with proteolytic processing of ECM-bound LTBP-1 
and simultaneous release of LL-TGF-β1 complexes from the ECM. This is consistent with 
earlier reports suggesting that the cleavage of LTBP-1 is a physiological mechanism for 
liberation of TGF-β from the ECM (Taipale et al. 1995; Dallas et al. 2002). The 
observation was cell type specific as treatment of human lung fibroblasts with PMA failed 
to induce processing of LTBP-1 or LL-TGF-β1. Furthermore, the soluble forms of 
processed LTBP-2 were not observed indicating that the phenomenon was specific for 
LTBP-1.  
In contrast to our expectations, neither serine proteases nor secreted MMPs, which 
have been implicated in TGF-β activation (Dallas et al. 2002; Yu and Stamenkovic 2000), 
were responsible for the processing of LTBP-1. Most notably, the activation of endothelial 
cells was coupled with increased MT-MMP activity and strong, specific induction of the 
expression of MT1-MMP. In addition to synthetic wide spectrum metalloproteinase 
inhibitors, TIMPs -2 and -3, which inhibit secreted MMPs and MT-MMPs, prevented the 
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proteolytic processing of LTBP-1 and LL-TGF-β1. The involvement of MT1-MMP was 
finally verified by suppressing the MT1-MMP expression by ~90 % via lentivirally 
introduced shRNAs. As a result, the LTBP-1 network appeared intact.  
The substrates of MT1-MMP include various ECM proteins such as collagen type I 
and IV, FN, laminin and vitronectin (Seiki 2003). It is expressed in advancing endothelial 
tip cells and downregulated at the time of stabilization and maturation of the vessel 
structure (Yana et al. 2007). In addition to degradation of ECM proteins, MT1-MMP may 
affect endothelial cell invasion by activating other MMPs and cleaving growth factors and 
their membrane-bound receptors (Seiki et al. 2003; Takino et al. 2004). Moreover, 
endothelial cell invasion and tube formation are inhibited by blocking MT1-MMP by 
TIMP-2 and TIMP-3 (Saunders et al. 2006). Our results suggest that MT1-MMP can also 
release ECM-bound LTBP-1 and TGF-β in conjunction with the remodeling of other 
subendothelial ECM proteins thus affecting pro/antiangiogenic balance. Although there is 
evidence that MT1-MMP can activate TGF-β (Karsdal et al. 2002), we could not confirm 
that in our experimental settings most likely due to too low levels of active TGF-β. This is 
in agreement with earlier observations which implicated the smooth muscle cells in the 
activation of TGF-β produced by endothelial cells (Sato et al. 1993).   
 
5.4 LTBPs -1 and -3 may differentially regulate TGF-β activity in 
mesothelioma 
TGF-β is an important regulator of tumor growth in mesothelioma as established by 
several mouse models of MM (Fitzpatrick et al. 1994; Marzo et al. 1997; Suzuki et al. 
2004; Suzuki et al. 2007). In addition, TGF-β activity in pleural fluids of MM patients is 
markedly higher than in primary lung cancer (Maeda et al. 1994; DeLong et al. 2005). 
Accordingly, we found that MM tumor cells, but not the stromal cells, were strongly 
positive for P-Smad2 indicative of active TGF-β signaling specifically in MM tumors. 
Importantly, the high P-Smad2 immunoreactivity correlated with poor survival of patients. 
By contrast, we detected abundant immunoreactivity of LTBP-1 in the stroma of MM 
tumors whereas the tumor tissue stained only weakly. This is in accordance with the 
observed expression of LTBP-1 in the stroma of gastrointestinal carcinoma but not in 
cancer cells (Mizoi et al. 1993). Our results indicated that TGF-β1 was the predominant 
isoform expressed in MM. Considering that TGF-β1 is also a strong inducer of LTBP-1 
production in normal lung fibroblasts (Weikkolainen et al. 2003) TGF-β produced by 
cancer cells may act in paracrine manner to stimulate the stromal cells leading to 
accumulation of LTBP-1. The stromal cells most likely respond differently to TGF-β than 
cancer cells. The reactions of cells are also dependent on the concentration of active TGF-
β which does not necessarily correlate with mRNA or protein levels and which is difficult 
to determine in tissues.   Tumor stroma plays an important role in driving cancer invasion 
(De Wever et al. 2008). TGF-β is able to convert normal fibroblasts of the stroma into 
myofibroblasts that stimulate invasion. Accumulation of LTBP-1-TGF-β complexes into 
the tumor stroma may provide the tumor cells a reservoir of TGF-β. On the other hand, as 
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LTBPs are often secreted in excess to TGF-β, LTBP-1 may alter the functions of the 
tumor stroma independently of TGF-β.  
The mRNA levels of LTBPs in tissue biopsies varied markedly. Nevertheless, we 
observed that the ratio of LTBP-1 mRNA levels to LTBP-3 levels was increased in 3/4 
tumor samples compared to the ratio in normal pleura. The samples were selected by an 
experienced pathologist and those containing more than 90% of tumor tissue were chosen 
for RNA analysis. However, the stromal components presumably contributed to the 
mRNA results.  
We used established mesothelioma cell lines to dissect the roles of these LTBPs in the 
regulation of TGF-β. The mRNA levels of LTBP-1 were higher in MM cells than in non-
malignant control cells. In contrast, LTBP-3 expression was reduced in MM cell lines, 
recapitulating the “switch” observed in tissue biopsies. As expected, the TGF-β activity 
was higher in MM cells. Suppressing the expression of LTBP-3 even more by siRNAs 
resulted in further increase in TGF-β activity. By contrast, downregulation of LTBP-1 
expression had no effect which could have been due to insufficient efficacy of the siRNA 
transfections.  The results suggest that LTBP-3 has an important role in targeting the LL-
TGF-β to the ECM in MM cells and preventing its activation. In general, LTBPs are 
needed for efficient secretion of TGF-β in normal cells but osteoblasts and some cancer 
cells are capable of secreting small latent complexes devoid of LTBP (Bonewald et al. 
1991; Olofsson et al. 1992). Moreover, defects in LTBP mediated ECM targeting can 
result in increased activation of TGF-β (Neptune et al. 2003; Mazzieri et al. 2005). Thus, 
it is possible that MM cells secrete and also activate small latent complexes when LTBP-3 
levels are reduced. Alternatively, the increased TGF-β activation could take place by 
mechanisms specific for other LTBPs, such as LTBP-1 or -4. For example, a change in 
cellular LTBP expression profile from predominant LTBP-3 expression to LTBP-1 
expression leads to a dramatic decrease in TGF-β activation during osteogenic 
differentiation of mesenchymal stem cells (Koli et al. 2008b). Our results from tumor 
biopsies, on the other hand, revealed a negative correlation between the LTBP-1 and P-
Smad2 immunoreactivity, suggesting that the LTBP-1 mediated activation of TGF-β is not 
the predominant activation mechanism in either MM tumors or stroma. We were not able 
to assess the localization of LTBP-3 or LTBP-4 and, therefore, especially the role of 
LTBP-4 remains to be elucidated. 
Although LTBP-3 requires association with TGF-β to be secreted from cells in vitro, it 
is possible that free LTBP-3 is deposited to the ECM in vivo. The free form might serve 
for other, possibly structural or adhesive, functions. If a shift in the ratio of LTBP-1 and 
LTBP-3 expression levels occurs in vivo, changes in their expression might, in addition to 
affecting TGF-β activity, alter the organization and consequently the functions of tumor 
stroma. 
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6 Perspectives 
LTBP-2 is an ECM molecule with poorly known functions. The results of this study 
revealed that in cell culture, LTBP-2 acts as an adhesive and migration supporting 
substrate for melanoma cells while it is anti-adhesive for various cell types of different 
origin (I). LTBP-2 is expressed in the dermis of developing mice (Shipley et al. 2000) and 
further investigations could be directed on its expression in human dermis and especially 
at sites of invading melanomas. Melanoma cells are derived from melanocytes which, in 
turn, originate from neural crest. The expression pattern of LTBP-2 in rat brain was 
recently observed to be much more restricted than patterns of the other LTBPs (Dobolyi 
and Palkovits 2008). Thus, it would be of interest to get more insight into the role of 
LTBP-2 in the brain. The in vivo functions of LTBP-2 have remained largely unknown. 
Important information could be obtained by generation of a conditional knock-out mouse 
to overcome the implantation problems of the traditional knock-out. 
The roles of LTBPs in cancers have not been extensively studied, not even in those 
where the role of TGF-β has been established. The results presented here suggest that 
LTBP-1 and LTBP-3 may differentially regulate TGF-β activity in mesothelioma (IV). 
Downregulation of LTBP-3 was associated with increased proliferation of MM cells in 
culture. Future studies should address the effects of LTBP silencing on the invasion of 
MM cells. In addition, LTBP-1 was found to be cleaved via MT1-MMP mediated 
mechanism during morphological activation of endothelial cells (III), a process which 
mimics angiogenesis, which, in turn, is important for tumor growth. The specific roles for 
different LTBP isoforms in the activation of TGF-β in cancer require further investigation.  
Current data revealed the important role of fibrillin-1 in the matrix deposition of 
LTBP-2 (II). The association of LTBPs -1 and -4 with fibrillin-1 has also been established 
(Ono et al. 2009). Further studies on interactions of different LTBPs with microfibrillar 
proteins, such as fibrillins and fibulins, would elucidate their roles for microfibril structure 
and function. It has been suggested that LTBP-2 regulates elastogenesis by interacting 
with fibulin-5 and preferentially depositing tropoelastin on fibrillin-1 containing 
microfibrils (Hirai et al. 2007). All these molecules are abundantly expressed in arterial 
vessels and LTBP-2 is secreted by endothelial cells. Thus, it would be important to 
address the role of LTBP-2 in the endothelial functions such as vessel formation. 
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